Induction	O
of	O
a	O
functional	O
vitamin	B-protein
D	I-protein
receptor	I-protein
in	O
all-trans-retinoic	O
acid-induced	O
monocytic	O
differentiation	O
of	O
M2-type	B-cell_line
leukemic	I-cell_line
blast	I-cell_line
cells	I-cell_line
.	O

Different	O
types	O
of	O
acute	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
blast	I-cell_type
cells	I-cell_type
were	O
induced	O
to	O
differentiate	O
in	O
vitro	O
with	O
all-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
vitamin	O
D3	O
(	O
VD	O
)	O
.	O

M0/M1	B-cell_line
leukemic	I-cell_line
cells	I-cell_line
are	O
not	O
sensitive	O
to	O
differentiating	O
agents	O
,	O
whereas	O
M3	B-cell_line
leukemic	I-cell_line
cells	I-cell_line
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	O
sensitive	O
to	O
VD	O
.	O

M2	B-cell_line
leukemic	I-cell_line
blast	I-cell_line
cells	I-cell_line
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O

To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2-type	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	B-cell_line
blast	I-cell_line
cells	I-cell_line
as	O
well	O
as	O
in	O
Kasumi-1	B-cell_line
cells	I-cell_line
(	O
an	O
acute	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
M2-type	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
.	O

Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	O
the	O
nuclear	O
abundance	O
of	O
VD	B-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O

VDR	B-protein
is	O
functionally	O
active	O
in	O
ATRA-treated	O
Kasumi-1	B-cell_line
cells	I-cell_line
because	O
it	O
efficiently	O
heterodimerizes	O
with	O
retinoid	B-protein
X	I-protein
receptor	I-protein
,	O
binds	O
to	O
a	O
DR3-type	B-DNA
vitamin	I-DNA
D-responsive	I-DNA
element	I-DNA
,	O
and	O
activates	O
the	O
transcription	O
of	O
a	O
vitamin	B-DNA
D-responsive	I-DNA
element-regulated	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Consistent	O
with	O
these	O
findings	O
,	O
VD-responsive	B-DNA
genes	I-DNA
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi-1	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	B-protein
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
59	NULL
,	NULL
3803-3811	NULL
,	NULL
August	NULL
1	NULL
,	NULL
1999	NULL
]	NULL
Induction	NULL
of	NULL
a	NULL
Functional	NULL
Vitamin	NULL
D	NULL
Receptor	NULL
in	NULL
all-trans-Retinoic	NULL
Acid-induced	NULL
Monocytic	NULL
Differentiation	NULL
of	NULL
M2-type	NULL
Leukemic	NULL
Blast	NULL
Cells	NULL
'	NULL
Rossella	NULL
Manfredini	NULL
,	NULL
Francesca	NULL
Trevisan	NULL
,	NULL
Alexis	NULL
Grande	NULL
,	NULL
Enrico	NULL
Tagliafico	NULL
,	NULL
Monica	NULL
Montanari	NULL
,	NULL
Roberto	NULL
Lemoli	NULL
,	NULL
Giuseppe	NULL
Visani	NULL
,	NULL
Sante	NULL
Tura	NULL
,	NULL
Stefano	NULL
Ferrari	NULL
,	NULL
and	NULL
Sergio	NULL
Ferrari	NULL
'	NULL
D	NULL
Airho	NULL
Seri	NULL
Dipartimento	NULL
di	NULL
Scienze	NULL
he	NULL
,	NULL
S	NULL
Istituto	NULL
di	NULL
Ematologia	NULL
L	NULL
&	NULL
A	NULL
Seragnoli	NULL
,	NULL
40138	NULL
Bologna	NULL
[	NULL
R.	NULL
L.	NULL
,	NULL
G.	NULL
V.	NULL
,	NULL
S.	NULL
T.	NULL
]	NULL
,	NULL
Italy	NULL
ABSTRACT	NULL
Different	NULL
types	NULL
of	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
blast	NULL
cells	NULL
were	NULL
induced	NULL
to	NULL
differentiate	NULL
in	NULL
vitro	NULL
with	NULL
all-frans-retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
and	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
(	NULL
VD	NULL
)	NULL
.	NULL

MO/M1	NULL
leukemic	NULL
cells	NULL
are	NULL
not	NULL
sensitive	NULL
to	NULL
differentiating	NULL
agents	NULL
,	NULL
whereas	NULL
M3	NULL
leukemic	NULL
cells	NULL
are	NULL
induced	NULL
to	NULL
undergo	NULL
granulocytic	NULL
differentiation	NULL
after	NULL
ATRA	NULL
treatment	NULL
but	NULL
are	NULL
not	NULL
sensitive	NULL
to	NULL
VD	NULL
.	NULL

M2	NULL
leukemic	NULL
blast	NULL
cells	NULL
behave	NULL
differently	NULL
because	NULL
they	NULL
undergo	NULL
monocytic	NULL
differentiation	NULL
with	NULL
both	NULL
the	NULL
differentiation	NULL
inducers	NULL
.	NULL

To	NULL
gain	NULL
some	NULL
insight	NULL
into	NULL
the	NULL
maturation	NULL
of	NULL
M2-type	NULL
leukemic	NULL
cells	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
monocytic	NULL
differentiation	NULL
induced	NULL
by	NULL
ATRA	NULL
and	NULL
VD	NULL
in	NULL
spontaneous	NULL
M2	NULL
blast	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
(	NULL
an	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
M2-type	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
ATRA	NULL
as	NULL
well	NULL
as	NULL
VD	NULL
efficiently	NULL
increases	NULL
the	NULL
nuclear	NULL
abundance	NULL
of	NULL
VD	NULL
receptor	NULL
(	NULL
VDR	NULL
)	NULL
and	NULL
promotes	NULL
monocytic	NULL
differentiation	NULL
.	NULL

VDR	NULL
is	NULL
functionally	NULL
active	NULL
in	NULL
ATRA-treated	NULL
Kasumi-1	NULL
cells	NULL
because	NULL
it	NULL
efficiently	NULL
heterodimerizes	NULL
with	NULL
retinoid	NULL
X	NULL
receptor	NULL
,	NULL
binds	NULL
to	NULL
a	NULL
DR3-type	NULL
vitamin	NULL
D-responsive	NULL
element	NULL
,	NULL
and	NULL
activates	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
vitamin	NULL
D-responsive	NULL
element-regulated	NULL
reporter	NULL
gene	NULL
.	NULL

Consistent	NULL
with	NULL
these	NULL
findings	NULL
,	NULL
VD-responsive	NULL
genes	NULL
are	NULL
induced	NULL
by	NULL
ATRA	NULL
treatment	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
genetic	NULL
program	NULL
underlying	NULL
monocytic	NULL
differentiation	NULL
is	NULL
activated	NULL
.	NULL

The	NULL
molecular	NULL
mechanism	NULL
by	NULL
which	NULL
ATRA	NULL
increases	NULL
the	NULL
nuclear	NULL
abundance	NULL
of	NULL
a	NULL
functional	NULL
VDR	NULL
is	NULL
still	NULL
unknown	NULL
,	NULL
but	NULL
our	NULL
data	NULL
clearly	NULL
indicate	NULL
that	NULL
the	NULL
M2	NULL
leukemic	NULL
cell	NULL
context	NULL
is	NULL
only	NULL
permissive	NULL
of	NULL
monocytic	NULL
differentiation	NULL
.	NULL

INTRODUCTION	NULL
Myelopoiesis	NULL
of	NULL
acute	NULL
leukemias	NULL
is	NULL
characterized	NULL
by	NULL
an	NULL
altered	NULL
balance	NULL
between	NULL
quiescent	NULL
,	NULL
cycling	NULL
,	NULL
and	NULL
differentiating	NULL
cells	NULL
.	NULL

AML	NULL
Â»	NULL
blast	NULL
cells	NULL
are	NULL
,	NULL
in	NULL
fact	NULL
,	NULL
mainly	NULL
arrested	NULL
in	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
are	NULL
unable	NULL
to	NULL
progress	NULL
spontaneously	NULL
toward	NULL
terminal	NULL
differentiation	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

The	NULL
growth	NULL
advantage	NULL
of	NULL
leukemic	NULL
blast	NULL
cells	NULL
is	NULL
therefore	NULL
achieved	NULL
mainly	NULL
through	NULL
a	NULL
prolonged	NULL
survival	NULL
time	NULL
,	NULL
probably	NULL
caused	NULL
by	NULL
a	NULL
maturation	NULL
arrest	NULL
and	NULL
an	NULL
inefficient	NULL
activation	NULL
of	NULL
the	NULL
apoptotic	NULL
program	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

A	NULL
unique	NULL
and	NULL
specific	NULL
genetic	NULL
disorder	NULL
has	NULL
been	NULL
discovered	NULL
in	NULL
APL	NULL
in	NULL
which	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
involves	NULL
the	NULL
genetic	NULL
loci	NULL
of	NULL
RARa	NULL
and	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
gene	NULL
(	NULL
5-8	NULL
)	NULL
.	NULL

Patients	NULL
affected	NULL
by	NULL
this	NULL
type	NULL
of	NULL
leukemia	NULL
can	NULL
undergo	NULL
complete	NULL
remission	NULL
when	NULL
treated	NULL
with	NULL
ATRA	NULL
,	NULL
which	NULL
induces	NULL
terminal	NULL
granulocytic	NULL
differentiation	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

It	NULL
is	NULL
thus	NULL
evident	NULL
that	NULL
Received	NULL
12/1/98	NULL
;	NULL
accepted	NULL
5/21/99	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

Supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Associazione	NULL
Italiana	NULL
per	NULL
la	NULL
Ricerca	NULL
sul	NULL
Cancro	NULL
and	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Consiglio	NULL
Nazionale	NULL
delle	NULL
Ricerche	NULL
(	NULL
Progetto	NULL
Finalizzato	NULL
:	NULL
Applicazioni	NULL
Cliniche	NULL
della	NULL
Ricerca	NULL
Oncologica	NULL
)	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Dipartimento	NULL
di	NULL
Scienze	NULL
Biomediche	NULL
,	NULL
Sezione	NULL
di	NULL
Chimica	NULL
Biologica	NULL
,	NULL
Via	NULL
Campi	NULL
287	NULL
,	NULL
Universita	NULL
di	NULL
Modena	NULL
e	NULL
Reggio	NULL
Emilia	NULL
,	NULL
41100	NULL
Modena	NULL
,	NULL
Italy	NULL
.	NULL

Phone	NULL
:	NULL
39059-428514	NULL
;	NULL
Fax	NULL
:	NULL
39059-428524	NULL
;	NULL
E-mail	NULL
:	NULL
sergio	NULL
@	NULL
unimo	NULL
.it	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
AML	NULL
,	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
;	NULL
RA	NULL
,	NULL
retinoic	NULL
acid	NULL
;	NULL
ATRA	NULL
,	NULL
all-trans-RA	NULL
;	NULL
VD	NULL
,	NULL
vitamin	NULL
D	NULL
;	NULL
;	NULL
VDR	NULL
,	NULL
vitamin	NULL
D	NULL
receptor	NULL
;	NULL
VDRE	NULL
,	NULL
vitamin	NULL
D	NULL
responsive	NULL
element	NULL
;	NULL
APL	NULL
,	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
;	NULL
RARa	NULL
,	NULL
RA	NULL
receptor	NULL
a	NULL
;	NULL
RARE	NULL
,	NULL
RA	NULL
responsive	NULL
element	NULL
;	NULL
RXR	NULL
,	NULL
retinoid	NULL
X	NULL
receptor	NULL
;	NULL
82m	NULL
,	NULL
B2-microglobulin	NULL
;	NULL
NE	NULL
,	NULL
nuclear	NULL
extract	NULL
;	NULL
CB	NULL
,	NULL
cytoplasmic	NULL
extract	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
TK	NULL
,	NULL
thymidine	NULL
kinase	NULL
;	NULL
DP	NULL
,	NULL
direct	NULL
primer	NULL
;	NULL
RP	NULL
,	NULL
reverse	NULL
primer	NULL
;	NULL
RT-PCR	NULL
,	NULL
reverse	NULL
transcription-PCR	NULL
;	NULL
HMSE-1	NULL
,	NULL
human	NULL
monocytic	NULL
serine	NULL
esterase	NULL
1	NULL
;	NULL
hOC	NULL
,	NULL
human	NULL
osteocalcin	NULL
;	NULL
IRE-1	NULL
,	NULL
interferon	NULL
regulatory	NULL
factor-1	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

di	NULL
Chimica	NULL
Biologica	NULL
,	NULL
Universita	NULL
di	NULL
Modena	NULL
e	NULL
di	NULL
Reggio	NULL
Emilia	NULL
,	NULL
41100	NULL
Modena	NULL
[	NULL
R.	NULL
M.	NULL
,	NULL
F.	NULL
T.	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
St.	NULL
F.	NULL
,	NULL
Se	NULL
.	NULL

F.	NULL
]	NULL
,	NULL
and	NULL
the	NULL
availability	NULL
of	NULL
compounds	NULL
capable	NULL
of	NULL
inducing	NULL
APL	NULL
blast	NULL
cells	NULL
to	NULL
differentiate	NULL
and	NULL
therefore	NULL
undergo	NULL
apoptosis	NULL
provides	NULL
an	NULL
opportunity	NULL
to	NULL
modify	NULL
the	NULL
course	NULL
of	NULL
the	NULL
malignancy	NULL
.	NULL

In	NULL
a	NULL
high	NULL
percentage	NULL
of	NULL
the	NULL
other	NULL
AML	NULL
types	NULL
,	NULL
genetic	NULL
abnormalities	NULL
are	NULL
extremely	NULL
heterogeneous	NULL
and	NULL
are	NULL
not	NULL
specific	NULL
(	NULL
11	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
only	NULL
20	NULL
%	NULL
of	NULL
M2-AML	NULL
is	NULL
characterized	NULL
by	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
a	NULL
very	NULL
low	NULL
percentage	NULL
of	NULL
cases	NULL
carry	NULL
t	NULL
(	NULL
6	NULL
;	NULL
9	NULL
)	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
very	NULL
few	NULL
cases	NULL
of	NULL
AML	NULL
are	NULL
characterized	NULL
by	NULL
t	NULL
(	NULL
3	NULL
;	NULL
21	NULL
)	NULL
(	NULL
14	NULL
)	NULL
.	NULL

In	NULL
principle	NULL
,	NULL
genetic	NULL
abnormalities	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
maturation	NULL
arrest	NULL
,	NULL
but	NULL
no	NULL
clear	NULL
correlation	NULL
can	NULL
be	NULL
made	NULL
between	NULL
the	NULL
level	NULL
of	NULL
the	NULL
differentiation	NULL
block	NULL
and	NULL
the	NULL
genetic	NULL
aberrations	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
the	NULL
M3-AML	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
acute	NULL
leukemia	NULL
blast	NULL
cells	NULL
express	NULL
several	NULL
growth	NULL
factor	NULL
receptors	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
,	NULL
they	NULL
are	NULL
poorly	NULL
sensitive	NULL
to	NULL
the	NULL
differentiation	NULL
activity	NULL
of	NULL
the	NULL
corresponding	NULL
cytokines	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
;	NULL
consequently	NULL
,	NULL
the	NULL
therapeutic	NULL
use	NULL
of	NULL
hematopoietic	NULL
growth	NULL
factors	NULL
in	NULL
AML	NULL
is	NULL
controversial	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Interest-ingly	NULL
,	NULL
cytokine	NULL
antagonists	NULL
can	NULL
block	NULL
leukemic	NULL
myeloid	NULL
cell	NULL
proliferation	NULL
due	NULL
to	NULL
an	NULL
autocrine	NULL
mechanism	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Despite	NULL
the	NULL
poor	NULL
evidence	NULL
that	NULL
exists	NULL
on	NULL
the	NULL
physiological	NULL
role	NULL
of	NULL
ATRA	NULL
and	NULL
VD	NULL
in	NULL
normal	NULL
hematopoiesis	NULL
,	NULL
these	NULL
inducers	NULL
could	NULL
be	NULL
suitable	NULL
to	NULL
force	NULL
the	NULL
differentiation	NULL
block	NULL
in	NULL
AML	NULL
blast	NULL
cells	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

It	NULL
is	NULL
well	NULL
known	NULL
that	NULL
VD	NULL
and	NULL
ATRA	NULL
exert	NULL
their	NULL
action	NULL
by	NULL
binding	NULL
to	NULL
specific	NULL
nuclear	NULL
receptors	NULL
with	NULL
high	NULL
affinity	NULL
.	NULL

These	NULL
nuclear	NULL
receptors	NULL
regulate	NULL
gene	NULL
expression	NULL
in	NULL
target	NULL
cells	NULL
by	NULL
binding	NULL
to	NULL
specific	NULL
DNA-responsive	NULL
elements	NULL
(	NULL
VDRE	NULL
and	NULL
RARE	NULL
)	NULL
via	NULL
heterodimerization	NULL
with	NULL
RXR	NULL
(	NULL
22	NULL
)	NULL
.	NULL

It	NULL
has	NULL
to	NULL
be	NULL
pointed	NULL
out	NULL
that	NULL
our	NULL
previous	NULL
studies	NULL
suggest	NULL
that	NULL
myeloid	NULL
precursors	NULL
at	NULL
all	NULL
stages	NULL
of	NULL
differentiation	NULL
are	NULL
equipped	NULL
with	NULL
the	NULL
machinery	NULL
required	NULL
to	NULL
trigger	NULL
the	NULL
VD-dependent	NULL
genetic	NULL
program	NULL
,	NULL
eventually	NULL
leading	NULL
to	NULL
terminal	NULL
differentiation	NULL
.	NULL

In	NULL
other	NULL
words	NULL
,	NULL
they	NULL
contain	NULL
VDR	NULL
protein	NULL
that	NULL
is	NULL
fully	NULL
active	NULL
in	NULL
binding	NULL
their	NULL
DNA	NULL
sites	NULL
and	NULL
in	NULL
promoting	NULL
transcription	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
response	NULL
to	NULL
VD	NULL
is	NULL
therefore	NULL
likely	NULL
to	NULL
depend	NULL
on	NULL
steps	NULL
located	NULL
downstream	NULL
of	NULL
the	NULL
nuclear	NULL
receptor/DNA	NULL
interaction	NULL
,	NULL
such	NULL
as	NULL
chromatin	NULL
structure	NULL
,	NULL
nu-cleosome	NULL
organization	NULL
,	NULL
and	NULL
gene-nuclear	NULL
matrix	NULL
interaction	NULL
.	NULL

To	NULL
gain	NULL
some	NULL
insight	NULL
into	NULL
the	NULL
differentiation	NULL
potential	NULL
of	NULL
different	NULL
types	NULL
of	NULL
AML	NULL
blast	NULL
cells	NULL
(	NULL
MO/M1	NULL
,	NULL
M2	NULL
,	NULL
and	NULL
M3	NULL
)	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
expression	NULL
levels	NULL
and	NULL
function	NULL
of	NULL
RARa	NULL
,	NULL
VDR	NULL
,	NULL
and	NULL
RXR	NULL
nuclear	NULL
receptors	NULL
(	NULL
22	NULL
,	NULL
24	NULL
)	NULL
and	NULL
the	NULL
ability	NULL
of	NULL
ATRA	NULL
or	NULL
VD	NULL
to	NULL
induce	NULL
terminal	NULL
granulocytic	NULL
or	NULL
monocytic	NULL
differentiation	NULL
in	NULL
vitro	NULL
(	NULL
25-27	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
a	NULL
monocytic	NULL
differentiation	NULL
window	NULL
exists	NULL
in	NULL
M2-type	NULL
blast	NULL
cells	NULL
because	NULL
ATRA	NULL
and	NULL
VD	NULL
can	NULL
only	NULL
trigger	NULL
monocytic	NULL
differentiation	NULL
in	NULL
M2-type	NULL
Kasumi-1	NULL
cells	NULL
(	NULL
28	NULL
)	NULL
as	NULL
well	NULL
as	NULL
in	NULL
spontaneous	NULL
leukemic	NULL
blast	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Cultures	NULL
and	NULL
Differentiation	NULL
.	NULL

Blast	NULL
cell	NULL
populations	NULL
were	NULL
obtained	NULL
by	NULL
leukapheresis	NULL
from	NULL
five	NULL
patients	NULL
with	NULL
MO/M1-AML	NULL
,	NULL
five	NULL
patients	NULL
with	NULL
M2-AML	NULL
,	NULL
and	NULL
three	NULL
patients	NULL
with	NULL
M3-AML	NULL
before	NULL
any	NULL
pharmacological	NULL
treatment	NULL
.	NULL

All	NULL
of	NULL
the	NULL
blast	NULL
cells	NULL
were	NULL
purified	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
to	NULL
obtain	NULL
extremely	NULL
homogeneous	NULL
populations	NULL
(	NULL
>	NULL
95	NULL
%	NULL
blast	NULL
cells	NULL
)	NULL
.	NULL

The	NULL
phenotype	NULL
in	NULL
each	NULL
case	NULL
was	NULL
defined	NULL
by	NULL
morphological	NULL
,	NULL
cytochemical	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
,	NULL
immunological	NULL
(	NULL
31	NULL
)	NULL
,	NULL
cytogenetic	NULL
,	NULL
and	NULL
molecular	NULL
criteria	NULL
,	NULL
at	NULL
least	NULL
for	NULL
the	NULL
molecular	NULL
analysis	NULL
of	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
(	NULL
32	NULL
)	NULL
and	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocations	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
blast	NULL
3803	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

MONOCYTIC	NULL
DIFFERENTIATION	NULL
OF	NULL
AML-M2	NULL
BLAST	NULL
CELLS	NULL
cell	NULL
populations	NULL
were	NULL
cultured	NULL
in	NULL
Iscove	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
2	NULL
mM	NULL
L-glutamine	NULL
and	NULL
20	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
.	NULL

Kasumi-1	NULL
(	NULL
M2	NULL
AML	NULL
)	NULL
and	NULL
HL-60	NULL
(	NULL
M2/M3	NULL
AML	NULL
)	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
15	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
.	NULL

Differentiation	NULL
was	NULL
induced	NULL
in	NULL
blast	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
cells	NULL
by	NULL
treatment	NULL
with	NULL
either	NULL
107Â°	NULL
m	NULL
ATRA	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Luis	NULL
,	NULL
MO	NULL
)	NULL
or	NULL
10~	NULL
'	NULL
m	NULL
VD	NULL
(	NULL
F.	NULL
Hoffmann-La	NULL
Roche	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
differentiation	NULL
was	NULL
monitored	NULL
by	NULL
direct	NULL
immunofluorescence	NULL
analysis	NULL
of	NULL
surface	NULL
markers	NULL
(	NULL
37	NULL
)	NULL
,	NULL
such	NULL
as	NULL
CD14	NULL
(	NULL
38	NULL
)	NULL
,	NULL
CD11b	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
CD45	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Each	NULL
antibody	NULL
was	NULL
incubated	NULL
directly	NULL
into	NULL
the	NULL
cellular	NULL
suspension	NULL
(	NULL
5-10	NULL
ug/10Â°	NULL
cells	NULL
)	NULL
for	NULL
20	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
cytofluorometric	NULL
analysis	NULL
.	NULL

Morphology	NULL
was	NULL
assessed	NULL
by	NULL
cytocen-trifugation	NULL
followed	NULL
by	NULL
May	NULL
Grunwald	NULL
Giemsa	NULL
staining	NULL
.	NULL

RNA	NULL
Analysis	NULL
.	NULL

Total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
guanidinium-cesium	NULL
chloride	NULL
centrifugation	NULL
technique	NULL
(	NULL
41	NULL
)	NULL
and	NULL
digested	NULL
with	NULL
RQ1-DNase	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
to	NULL
avoid	NULL
DNA	NULL
contamination	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
42	NULL
)	NULL
.	NULL

RT-PCR	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
a	NULL
previously	NULL
described	NULL
technique	NULL
(	NULL
42	NULL
)	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
oligodeoxynucleotide	NULL
primers	NULL
specific	NULL
for	NULL
RARa	NULL
(	NULL
43	NULL
)	NULL
,	NULL
RXR	NULL
(	NULL
44	NULL
)	NULL
,	NULL
VDR	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
,	NULL
CD14	NULL
(	NULL
47	NULL
)	NULL
,	NULL
HMSE-1	NULL
(	NULL
48	NULL
)	NULL
,	NULL
hOC	NULL
(	NULL
49	NULL
)	NULL
,	NULL
and	NULL
2m	NULL
,	NULL
(	NULL
50	NULL
)	NULL
.	NULL

The	NULL
oligonucleotides	NULL
used	NULL
as	NULL
DPs	NULL
or	NULL
RPs	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
(	NULL
a	NULL
)	NULL
RARa	NULL
&	NULL
-DP	NULL
(	NULL
5'-CCAGACTGTCTGCCTCCCTIT-3	NULL
'	NULL
)	NULL
and	NULL
RAR	NULL
&	NULL
-RP	NULL
(	NULL
5'-GTTTCGGTCGTIT-TCTCACAGAC-3	NULL
``	NULL
)	NULL
;	NULL
(	NULL
b	NULL
)	NULL
RXRa-DP	NULL
(	NULL
5-CATTTCCTGCCGCTCGATTTC-3	NULL
``	NULL
)	NULL
and	NULL
(	NULL
5-CTGCTGCTGACGGGGTTCAT-3	NULL
'	NULL
)	NULL
;	NULL
(	NULL
c	NULL
)	NULL
VDR-DP	NULL
(	NULL
5'-GGAGACTTTGACCGGAACGTG-3	NULL
'	NULL
)	NULL
and	NULL
VDR-RP	NULL
(	NULL
5-GAACTGGCA-GAAGTCGGAGTA-3	NULL
'	NULL
)	NULL
;	NULL
(	NULL
d	NULL
)	NULL
VDR	NULL
primary	NULL
transcript-DP	NULL
(	NULL
5'-CAGTGACGT-GACCAAAGGTATGCCTAG-3	NULL
'	NULL
)	NULL
and	NULL
VDR	NULL
primary	NULL
transcript-RP	NULL
(	NULL
5'-GGGAGACGATGCAGATGGCCATGAGCA-3	NULL
``	NULL
)	NULL
;	NULL
(	NULL
e	NULL
)	NULL
CDI14-DP	NULL
(	NULL
5'-TCC-AGAGCCTGTCCGGAGCTCAGA-3	NULL
'	NULL
)	NULL
and	NULL
CDI4-RP	NULL
(	NULL
5-GCGTTCGC-CCAGTCCAGGATTGTCA-3	NULL
'	NULL
)	NULL
;	NULL
(	NULL
/	NULL
)	NULL
HMSE-1-DP	NULL
(	NULL
Â§-CCTCCTATGTG-CACCCAAGAT-3	NULL
'	NULL
)	NULL
and	NULL
HMSE-1-RP	NULL
(	NULL
5-GCATCCC-ATCAATCACAG-TGC-3	NULL
'	NULL
)	NULL
;	NULL
(	NULL
g	NULL
)	NULL
hOC-DP	NULL
(	NULL
5-GAGCCCTCACACTCCTCGCCCTATT-3	NULL
'	NULL
)	NULL
and	NULL
hOC-RP	NULL
(	NULL
5-GTAGAAGCGCCGATAGGCCTCCTGA-3	NULL
``	NULL
)	NULL
;	NULL
and	NULL
(	NULL
A	NULL
)	NULL
B2m-DP	NULL
(	NULL
5-CTCGCGCTACTCTCTCTTTCT-3	NULL
'	NULL
)	NULL
and	NULL
B2m-RP	NULL
(	NULL
5-TCCATTCT-TCAGTAAGTCAACT-3	NULL
'	NULL
.	NULL

The	NULL
primers	NULL
used	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
and	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
to	NULL
monitor	NULL
p21	NULL
(	NULL
51	NULL
)	NULL
,	NULL
E3	NULL
(	NULL
52	NULL
)	NULL
,	NULL
and	NULL
IRF-1	NULL
(	NULL
53	NULL
)	NULL
expression	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
NEs	NULL
and	NULL
CEs	NULL
.	NULL

NEs	NULL
and	NULL
CEs	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
different	NULL
myeloid	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
23	NULL
,	NULL
55	NULL
)	NULL
,	NULL
before	NULL
and	NULL
after	NULL
12	NULL
h	NULL
of	NULL
VD	NULL
treatment	NULL
.	NULL

Western	NULL
Blotting	NULL
.	NULL

Western	NULL
blotting	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Burnette	NULL
(	NULL
56	NULL
)	NULL
,	NULL
with	NULL
minor	NULL
modifications	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
9A7y	NULL
rat	NULL
monoclonal	NULL
anti-VDR	NULL
(	NULL
ABR	NULL
;	NULL
Affinity	NULL
Bioreagents	NULL
,	NULL
Golden	NULL
,	NULL
CO	NULL
)	NULL
and	NULL
Rpo	NULL
(	NULL
F	NULL
)	NULL
rabbit	NULL
polyclonal	NULL
anti-RARa	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Prof.	NULL
P.	NULL
Chambon	NULL
,	NULL
Institute	NULL
de	NULL
Genetique	NULL
et	NULL
de	NULL
Biologie	NULL
Moleculaire	NULL
et	NULL
Cellulaire	NULL
,	NULL
IlIkirch	NULL
Cedex	NULL
,	NULL
France	NULL
)	NULL
were	NULL
used	NULL
as	NULL
primary	NULL
antibody	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
the	NULL
VDR	NULL
and	NULL
RARa	NULL
proteins	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
detection	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
the	NULL
enhanced	NULL
chemi-luminescence	NULL
method	NULL
(	NULL
Amersham	NULL
Life	NULL
Science	NULL
,	NULL
Little	NULL
Chalfont	NULL
,	NULL
United	NULL
King-dom	NULL
)	NULL
.	NULL

Gel	NULL
Shift	NULL
Assay	NULL
.	NULL

Oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
an	NULL
automated	NULL
solid-phase	NULL
DNA	NULL
synthesizer	NULL
(	NULL
Model	NULL
394	NULL
;	NULL
Applied	NULL
Biosystem	NULL
,	NULL
Inc.	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
with	NULL
the	NULL
standard	NULL
phosphoramidite	NULL
chemistry	NULL
and	NULL
purified	NULL
by	NULL
PAGE	NULL
,	NULL
followed	NULL
by	NULL
electroelution	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
57	NULL
)	NULL
.	NULL

The	NULL
DR3	NULL
oligonucleotide	NULL
5'-AGCTTCAGGTCAAGGAGGTCAGAGAGC-3	NULL
'	NULL
(	NULL
58	NULL
)	NULL
and	NULL
its	NULL
complement	NULL
were	NULL
synthesized	NULL
and	NULL
used	NULL
as	NULL
probe	NULL
in	NULL
the	NULL
gel	NULL
shift	NULL
assay	NULL
.	NULL

Oligonucleotide	NULL
annealing	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
58	NULL
,	NULL
59	NULL
)	NULL
.	NULL

The	NULL
double-stranded	NULL
oligonucleotide	NULL
was	NULL
further	NULL
purified	NULL
by	NULL
PAGE	NULL
,	NULL
electrocluted	NULL
,	NULL
and	NULL
5	NULL
'	NULL
end-labeled	NULL
(	NULL
100	NULL
ng	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
60	NULL
)	NULL
.	NULL

Specific	NULL
radioactivity	NULL
ranged	NULL
from	NULL
1-3	NULL
X	NULL
10Â°	NULL
cpm/ug	NULL
DNA	NULL
.	NULL

Gel	NULL
retardation	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
60	NULL
)	NULL
.	NULL

The	NULL
following	NULL
mAbs	NULL
were	NULL
used	NULL
(	NULL
a	NULL
)	NULL
9A7y	NULL
(	NULL
rat	NULL
monoclonal	NULL
anti-VDR	NULL
;	NULL
ABR	NULL
;	NULL
Affinity	NULL
Bioreagents	NULL
)	NULL
;	NULL
(	NULL
b	NULL
)	NULL
4RX-1D12	NULL
(	NULL
mouse	NULL
monoclonal	NULL
anti-RXR	NULL
Â«	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-y	NULL
;	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
P.	NULL
Chambon	NULL
)	NULL
;	NULL
and	NULL
(	NULL
c	NULL
)	NULL
AbIa	NULL
(	NULL
F	NULL
;	NULL
mouse	NULL
monoclonal	NULL
anti-RARa	NULL
;	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
P.	NULL
Chambon	NULL
)	NULL
.	NULL

In	NULL
all	NULL
of	NULL
the	NULL
gel	NULL
shift	NULL
mobility	NULL
experiments	NULL
,	NULL
the	NULL
VDR	NULL
specificity	NULL
of	NULL
the	NULL
shifted	NULL
bands	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
disruption	NULL
of	NULL
shift	NULL
complex	NULL
when	NULL
anti-	NULL
VDR	NULL
antibody	NULL
was	NULL
added	NULL
.	NULL

In	NULL
several	NULL
control	NULL
experiments	NULL
,	NULL
VDRE	NULL
specificity	NULL
was	NULL
also	NULL
confirmed	NULL
by	NULL
adding	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
cold	NULL
VDRE	NULL
oligonucleotides	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
use	NULL
of	NULL
anti-RARa	NULL
or	NULL
anti-RXRa	NULL
mAb	NULL
has	NULL
the	NULL
ability	NULL
to	NULL
detect	NULL
a	NULL
supershifted	NULL
band	NULL
when	NULL
these	NULL
nuclear	NULL
receptors	NULL
are	NULL
complexed	NULL
in	NULL
a	NULL
heterodimeric	NULL
conformation	NULL
.	NULL

All	NULL
antibodies	NULL
were	NULL
added	NULL
to	NULL
the	NULL
samples	NULL
at	NULL
1:20	NULL
final	NULL
dilution	NULL
.	NULL

The	NULL
reaction	NULL
mixtures	NULL
were	NULL
then	NULL
loaded	NULL
on	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
(	NULL
45	NULL
mm	NULL
Tris	NULL
,	NULL
45	NULL
mm	NULL
boric	NULL
acid	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
,	NULL
prerun	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Finally	NULL
the	NULL
gel	NULL
was	NULL
fixed	NULL
,	NULL
vacuum	NULL
dried	NULL
,	NULL
and	NULL
exposed	NULL
to	NULL
X-ray	NULL
films	NULL
for	NULL
2-4	NULL
h.	NULL
Cell	NULL
Transfection	NULL
.	NULL

The	NULL
following	NULL
plasmids	NULL
were	NULL
used	NULL
in	NULL
the	NULL
transfection	NULL
experiments	NULL
:	NULL
(	NULL
a	NULL
)	NULL
pCMVB	NULL
(	NULL
Clontech	NULL
Laboratories	NULL
Inc.	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
a	NULL
-galactosidase	NULL
expression	NULL
vector	NULL
;	NULL
(	NULL
b	NULL
)	NULL
pOsteo/CABP-CAT	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
VDRE	NULL
of	NULL
the	NULL
hOC	NULL
gene	NULL
(	NULL
-511/	NULL
-480	NULL
;	NULL
Ref	NULL
.	NULL

61	NULL
)	NULL
and	NULL
the	NULL
minimal	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
chicken	NULL
Calbindin	NULL
gene	NULL
(	NULL
62	NULL
)	NULL
;	NULL
and	NULL
(	NULL
c	NULL
)	NULL
pTK/RAREGB2-CAT	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Prof.	NULL
V.	NULL
Colantuoni	NULL
,	NULL
Universita	NULL
di	NULL
Napoli	NULL
``	NULL
Federico	NULL
II	NULL
``	NULL
,	NULL
Napoli	NULL
,	NULL
Italy	NULL
)	NULL
,	NULL
containing	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
RARERB2	NULL
and	NULL
the	NULL
minimal	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
human	NULL
TK	NULL
gene	NULL
(	NULL
-104/+51	NULL
)	NULL
.	NULL

Cells	NULL
(	NULL
2.5	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
with	NULL
30	NULL
ug	NULL
of	NULL
pOsteo/CABP-CAT	NULL
or	NULL
pTK/RAREB2-CAT	NULL
plasmid	NULL
and	NULL
3	NULL
pg	NULL
of	NULL
pCMV	NULL
B	NULL
plasmid	NULL
.	NULL

Electroporation	NULL
was	NULL
performed	NULL
at	NULL
250	NULL
V	NULL
and	NULL
960	NULL
F	NULL
(	NULL
Gene	NULL
Pulser	NULL
Apparatus	NULL
;	NULL
Bio-Rad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
15	NULL
%	NULL
FCS	NULL
with	NULL
or	NULL
without	NULL
VD	NULL
or	NULL
ATRA	NULL
for	NULL
48	NULL
h	NULL
and	NULL
then	NULL
harvested	NULL
for	NULL
B-galactosidase	NULL
and	NULL
CAT	NULL
assay	NULL
(	NULL
63	NULL
)	NULL
.	NULL

B-Galactosidase	NULL
activity	NULL
was	NULL
used	NULL
to	NULL
normalize	NULL
the	NULL
amount	NULL
of	NULL
cell	NULL
extract	NULL
to	NULL
be	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
(	NULL
63	NULL
)	NULL
.	NULL

RESULTS	NULL
Differentiation	NULL
Capacity	NULL
of	NULL
Myeloid	NULL
Blast	NULL
Cells	NULL
Arrested	NULL
at	NULL
Different	NULL
Levels	NULL
of	NULL
Maturation	NULL
after	NULL
5	NULL
Days	NULL
of	NULL
Treatment	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
shows	NULL
the	NULL
results	NULL
obtained	NULL
by	NULL
cytofluorometric	NULL
analysis	NULL
of	NULL
CD14	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD45	NULL
expression	NULL
in	NULL
leukemic	NULL
cell	NULL
populations	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
the	NULL
CD11b	NULL
marker	NULL
is	NULL
associated	NULL
with	NULL
granulocytic	NULL
differentiation	NULL
,	NULL
whereas	NULL
the	NULL
simultaneous	NULL
induction	NULL
of	NULL
CD14	NULL
and	NULL
CD11b	NULL
is	NULL
associated	NULL
with	NULL
monocytic	NULL
differentiation	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
panleukocytic	NULL
CD45	NULL
antigen	NULL
indicates	NULL
the	NULL
percentage	NULL
of	NULL
cell	NULL
viability	NULL
.	NULL

Fig	NULL
.	NULL

14	NULL
shows	NULL
the	NULL
results	NULL
obtained	NULL
in	NULL
five	NULL
cases	NULL
of	NULL
MO/M1-AML	NULL
populations	NULL
:	NULL
all	NULL
cell	NULL
populations	NULL
studied	NULL
express	NULL
a	NULL
high	NULL
level	NULL
of	NULL
â¬D45	NULL
and	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
CD14	NULL
and	NULL
CD11b	NULL
before	NULL
and	NULL
after	NULL
treatment	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
surface	NULL
marker	NULL
expression	NULL
in	NULL
five	NULL
cases	NULL
of	NULL
M2-AML	NULL
populations	NULL
before	NULL
differentiation	NULL
treatment	NULL
is	NULL
characterized	NULL
by	NULL
a	NULL
high	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
CD45	NULL
and	NULL
a	NULL
very	NULL
low	NULL
expression	NULL
of	NULL
CD14	NULL
and	NULL
CD11b	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

After	NULL
VD	NULL
or	NULL
ATRA	NULL
treatment	NULL
,	NULL
a	NULL
high	NULL
percentage	NULL
of	NULL
cells	NULL
express	NULL
CD14	NULL
and	NULL
CD11b	NULL
,	NULL
indicating	NULL
that	NULL
monocytic	NULL
differentiation	NULL
occurs	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
39	NULL
)	NULL
,	NULL
independent	NULL
of	NULL
the	NULL
inducer	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Granulocytic	NULL
differentiation	NULL
is	NULL
observed	NULL
when	NULL
leukemic	NULL
blast	NULL
cells	NULL
of	NULL
the	NULL
M3	NULL
type	NULL
are	NULL
treated	NULL
with	NULL
ATRA	NULL
;	NULL
in	NULL
fact	NULL
,	NULL
only	NULL
CD11b	NULL
is	NULL
clearly	NULL
induced	NULL
in	NULL
all	NULL
populations	NULL
studied	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
VD	NULL
treatment	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
these	NULL
cells	NULL
.	NULL

Morphological	NULL
analysis	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
pattern	NULL
of	NULL
surface	NULL
marker	NULL
expression	NULL
in	NULL
all	NULL
types	NULL
of	NULL
AML	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

VDR	NULL
,	NULL
RARa	NULL
,	NULL
and	NULL
RXR	NULL
Expression	NULL
in	NULL
MO/M1	NULL
,	NULL
M2	NULL
,	NULL
and	NULL
M3-AML	NULL
Blast	NULL
Cells	NULL
.	NULL

To	NULL
clarify	NULL
whether	NULL
the	NULL
different	NULL
sensitivity	NULL
to	NULL
ATRA	NULL
or	NULL
VD	NULL
could	NULL
depend	NULL
on	NULL
the	NULL
differential	NULL
expression	NULL
of	NULL
VDR	NULL
,	NULL
RARa	NULL
,	NULL
and	NULL
RXR	NULL
nuclear	NULL
receptors	NULL
,	NULL
we	NULL
performed	NULL
RT-PCR	NULL
analysis	NULL
in	NULL
all	NULL
types	NULL
of	NULL
AML	NULL
blast	NULL
cells	NULL
.	NULL

Fig	NULL
.	NULL

2A	NULL
shows	NULL
that	NULL
RARa	NULL
,	NULL
RXRa	NULL
,	NULL
and	NULL
VDR	NULL
mRNAs	NULL
are	NULL
present	NULL
in	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
spontaneous	NULL
leukemic	NULL
cell	NULL
populations	NULL
studied	NULL
,	NULL
although	NULL
with	NULL
a	NULL
different	NULL
abundance	NULL
.	NULL

The	NULL
only	NULL
exceptions	NULL
are	NULL
a	NULL
MO/M1	NULL
population	NULL
expressing	NULL
a	NULL
low	NULL
level	NULL
of	NULL
RARa	NULL
mRNA	NULL
and	NULL
no	NULL
VDR	NULL
mRNA	NULL
(	NULL
Lane	NULL
4	NULL
)	NULL
and	NULL
one	NULL
M3-AML	NULL
population	NULL
(	NULL
Lane	NULL
12	NULL
)	NULL
in	NULL
which	NULL
VDR	NULL
mRNA	NULL
is	NULL
not	NULL
detectable	NULL
.	NULL

RT-PCR	NULL
products	NULL
of	NULL
B2m	NULL
mRNA	NULL
used	NULL
to	NULL
monitor	NULL
the	NULL
amount	NULL
of	NULL
the	NULL
RNA	NULL
in	NULL
each	NULL
sample	NULL
are	NULL
also	NULL
reported	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
Lanes	NULL
1-13	NULL
.	NULL

Nuclear	NULL
receptor	NULL
expression	NULL
is	NULL
detectable	NULL
in	NULL
Kasumi-1	NULL
(	NULL
M2-type	NULL
AML	NULL
)	NULL
and	NULL
HL-60	NULL
(	NULL
M2/M3-type	NULL
AML	NULL
)	NULL
cell	NULL
lines	NULL
before	NULL
and	NULL
after	NULL
12	NULL
h	NULL
of	NULL
ATRA	NULL
or	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

3804	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

MONOCYTIC	NULL
DIFFERENTIATION	NULL
OF	NULL
AML-M2	NULL
BLAST	NULL
CELLS	NULL
100	NULL
Co	NULL
o	NULL
@	NULL
o	NULL
40	NULL
%	NULL
of	NULL
positive	NULL
cells	NULL
20	NULL
100	NULL
80	NULL
60	NULL
40	NULL
%	NULL
of	NULL
positive	NULL
cells	NULL
20	NULL
100	NULL
80	NULL
60	NULL
40	NULL
%	NULL
of	NULL
positive	NULL
cells	NULL
20	NULL
ag	NULL
b	NULL
2	NULL
b	NULL
%	NULL
,	NULL
*	NULL
*	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Expression	NULL
of	NULL
CD45	NULL
,	NULL
CD14	NULL
,	NULL
and	NULL
CD11b	NULL
in	NULL
MO/M1	NULL
,	NULL
M2	NULL
,	NULL
and	NULL
M3-AML	NULL
cell	NULL
populations	NULL
.	NULL

The	NULL
histograms	NULL
show	NULL
the	NULL
levels	NULL
of	NULL
expression	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
,	NULL
of	NULL
CD45	NULL
(	NULL
Ratched	NULL
bars	NULL
)	NULL
,	NULL
CD14	NULL
(	NULL
L	NULL
]	NULL
)	NULL
,	NULL
and	NULL
CD11b	NULL
(	NULL
MI	NULL
)	NULL
surface	NULL
markers	NULL
in	NULL
AML	NULL
MO/MI1	NULL
(	NULL
five	NULL
blast	NULL
cell	NULL
populations	NULL
;	NULL
A	NULL
)	NULL
,	NULL
AML	NULL
M2	NULL
(	NULL
five	NULL
blast	NULL
cell	NULL
populations	NULL
;	NULL
B	NULL
)	NULL
,	NULL
and	NULL
AML	NULL
M3	NULL
(	NULL
three	NULL
blast	NULL
cell	NULL
populations	NULL
;	NULL
C	NULL
)	NULL
cells	NULL
treated	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
for	NULL
5	NULL
days	NULL
or	NULL
left	NULL
untreated	NULL
.	NULL

The	NULL
values	NULL
are	NULL
expressed	NULL
in	NULL
percentages	NULL
.	NULL

The	NULL
reported	NULL
results	NULL
are	NULL
the	NULL
average	NULL
of	NULL
three	NULL
different	NULL
sets	NULL
of	NULL
experiments	NULL
.	NULL

Variability	NULL
in	NULL
each	NULL
experiment	NULL
was	NULL
less	NULL
than	NULL
10	NULL
%	NULL
.	NULL

Furthermore	NULL
,	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
can	NULL
be	NULL
detected	NULL
by	NULL
RT-PCR	NULL
in	NULL
only	NULL
one	NULL
of	NULL
five	NULL
cases	NULL
of	NULL
M2-AML	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
C.	NULL
C.	NULL
)	NULL
,	NULL
whereas	NULL
all	NULL
M3-AMLs	NULL
were	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
positive	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

VDR	NULL
Protein	NULL
Expression	NULL
in	NULL
MO/M1	NULL
,	NULL
M2	NULL
,	NULL
and	NULL
M3-AML	NULL
Blast	NULL
Cells	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
to	NULL
detect	NULL
VDR	NULL
protein	NULL
in	NULL
CEs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
NEs	NULL
obtained	NULL
from	NULL
MO/MI1	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
,	NULL
M2	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
and	NULL
M3	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
AML	NULL
blast	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
show	NULL
that	NULL
no	NULL
VDR	NULL
can	NULL
be	NULL
detected	NULL
before	NULL
VD	NULL
treatment	NULL
in	NULL
either	NULL
the	NULL
cytoplasmic	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
the	NULL
nuclear	NULL
compartment	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A-C	NULL
,	NULL
Lane	NULL
1	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
VDR	NULL
is	NULL
clearly	NULL
present	NULL
in	NULL
NEs	NULL
of	NULL
all	NULL
types	NULL
of	NULL
AML	NULL
blast	NULL
cells	NULL
after	NULL
12	NULL
h	NULL
of	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3A-C	NULL
,	NULL
Lane	NULL
3	NULL
)	NULL
.	NULL

Surpris-ingly	NULL
,	NULL
12	NULL
h	NULL
of	NULL
ATRA	NULL
treatment	NULL
causes	NULL
the	NULL
appearance	NULL
of	NULL
VDR	NULL
only	NULL
in	NULL
M2	NULL
blast	NULL
cell	NULL
NEs	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
Lane	NULL
2	NULL
)	NULL
,	NULL
and	NULL
not	NULL
in	NULL
the	NULL
other	NULL
types	NULL
of	NULL
blast	NULL
cells	NULL
studied	NULL
.	NULL

The	NULL
same	NULL
VDR	NULL
expression	NULL
pattern	NULL
is	NULL
observed	NULL
in	NULL
the	NULL
other	NULL
four	NULL
cases	NULL
of	NULL
this	NULL
type	NULL
of	NULL
AML	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

P	NULL
Q	NULL
CE	NULL
AML-	NULL
M1	NULL
AML-M2	NULL
___	NULL
AML-M3	NULL
g	NULL
r	NULL
1	NULL
Â©	NULL
g	NULL
s	NULL
0	NULL
3	NULL
o	NULL
m	NULL
m	NULL
oom	NULL
m	NULL
G	NULL
w	NULL
G	NULL
=	NULL
(	NULL
A	NULL
a	NULL
3	NULL
G	NULL
o	NULL
a	NULL
o	NULL
Go	NULL
G	NULL
<	NULL
w	NULL
3	NULL
<	NULL
Z	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
f1	NULL
12	NULL
1314	NULL
<	NULL
a	NULL
fas	NULL
son	NULL
.	NULL

$	NULL
2	NULL
f	NULL
Eo	NULL
o	NULL
JLo	NULL
ZI	NULL
E	NULL
<	NULL
.	NULL

s	NULL
Ss	NULL
s	NULL
5	NULL
Â§	NULL
o	NULL
o	NULL
o	NULL
3	NULL
5	NULL
50	NULL
C	NULL
a	NULL
3	NULL
3	NULL
$	NULL
2	NULL
2	NULL
Â§	NULL
E	NULL
To	NULL
To	NULL
Â¥	NULL
vo	NULL
S	NULL
Z	NULL
B	NULL
RARa_	NULL
--	NULL
527bp	NULL
VDR_	NULL
--	NULL
419bp	NULL
ji	NULL
-	NULL
``	NULL
OT	NULL
62m_-_162bp	NULL
-x	NULL
o	NULL
t	NULL
4	NULL
5	NULL
6	NULL
~	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Detection	NULL
by	NULL
RT-PCR	NULL
of	NULL
RARa	NULL
,	NULL
VDR	NULL
,	NULL
and	NULL
RXR	NULL
mRNAs	NULL
in	NULL
AML-MO/M1	NULL
,	NULL
M2	NULL
,	NULL
and	NULL
M3	NULL
blast	NULL
cell	NULL
populations	NULL
as	NULL
well	NULL
as	NULL
in	NULL
HL-60	NULL
and	NULL
Kasumi-1	NULL
cells	NULL
.	NULL

Panel	NULL
A	NULL
:	NULL
Lanes	NULL
1-5	NULL
,	NULL
five	NULL
cases	NULL
of	NULL
AML-MO/M1	NULL
;	NULL
Lanes	NULL
6-10	NULL
,	NULL
five	NULL
cases	NULL
of	NULL
AML-M2	NULL
;	NULL
Lanes	NULL
11-13	NULL
,	NULL
three	NULL
cases	NULL
of	NULL
AML-M3	NULL
;	NULL
Lane	NULL
14	NULL
,	NULL
negative	NULL
control	NULL
performed	NULL
without	NULL
the	NULL
cDNA	NULL
template	NULL
.	NULL

Panel	NULL
B	NULL
:	NULL
Lane	NULL
1	NULL
,	NULL
proliferating	NULL
HL-60	NULL
cells	NULL
;	NULL
Lane	NULL
2	NULL
,	NULL
HL-60	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
;	NULL
Lane	NULL
3	NULL
,	NULL
HL-60	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
VD	NULL
;	NULL
Lane	NULL
4	NULL
,	NULL
proliferating	NULL
Kasumi-1	NULL
cells	NULL
;	NULL
Lane	NULL
5	NULL
,	NULL
Kasumi-1	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
;	NULL
Lane	NULL
6	NULL
,	NULL
Kasumi-1	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
VD	NULL
;	NULL
Lane	NULL
7	NULL
,	NULL
negative	NULL
control	NULL
performed	NULL
without	NULL
the	NULL
cDNA	NULL
template	NULL
.	NULL

RT-PCR	NULL
products	NULL
of	NULL
B2m	NULL
mRNA	NULL
are	NULL
shown	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
both	NULL
panels	NULL
.	NULL

The	NULL
different	NULL
genes	NULL
studied	NULL
and	NULL
the	NULL
size	NULL
of	NULL
the	NULL
amplified	NULL
fragments	NULL
are	NULL
labeled	NULL
on	NULL
the	NULL
left	NULL
and	NULL
right	NULL
side	NULL
of	NULL
each	NULL
panel	NULL
,	NULL
respectively	NULL
.	NULL

3805	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

MONOCYTIC	NULL
DIFFERENTIATION	NULL
OF	NULL
AML-M2	NULL
BLAST	NULL
CELLS	NULL
LL	NULL
Z	NULL
a	NULL
2	NULL
-w	NULL
d	NULL
*	NULL
w	NULL
E	NULL
Â¢	NULL
5	NULL
5	NULL
4	NULL
2	NULL
A	NULL
ex	NULL
Â»	NULL
-53	NULL
kDa	NULL
A	NULL
.	NULL

B	NULL
aw	NULL
Â»	NULL
am	NULL
Â»	NULL
-53	NULL
kDa	NULL
Â©	NULL
a	NULL
Â»	NULL
-53	NULL
kDa	NULL
D	NULL
wae	NULL
awwae	NULL
we	NULL
-54	NULL
kDa	NULL
1	NULL
2	NULL
3	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
VDR	NULL
expression	NULL
in	NULL
AML-MO/M1	NULL
,	NULL
M2	NULL
,	NULL
and	NULL
M3	NULL
blast	NULL
cell	NULL
populations	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
VDR	NULL
protein	NULL
was	NULL
assayed	NULL
in	NULL
NEs	NULL
obtained	NULL
from	NULL
AML-MO/M1	NULL
(	NULL
A	NULL
)	NULL
,	NULL
M2	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
M3	NULL
(	NULL
C	NULL
)	NULL
blast	NULL
cell	NULL
populations	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
or	NULL
left	NULL
untreated	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
NEs	NULL
of	NULL
untreated	NULL
cells	NULL
;	NULL
Lane	NULL
2	NULL
,	NULL
NEs	NULL
of	NULL
ATRA-treated	NULL
cells	NULL
;	NULL
Lane	NULL
3	NULL
,	NULL
NEs	NULL
of	NULL
VD-treated	NULL
cells	NULL
.	NULL

D	NULL
,	NULL
RARa	NULL
expression	NULL
in	NULL
NEs	NULL
obtained	NULL
from	NULL
AML-M2	NULL
blast	NULL
cell	NULL
populations	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
or	NULL
left	NULL
untreated	NULL
.	NULL

The	NULL
estimated	NULL
molecular	NULL
mass	NULL
of	NULL
VDR	NULL
and	NULL
RARa	NULL
is	NULL
indicated	NULL
on	NULL
the	NULL
right	NULL
side	NULL
of	NULL
each	NULL
panel	NULL
.	NULL

RARa	NULL
protein	NULL
is	NULL
clearly	NULL
detected	NULL
in	NULL
NEs	NULL
obtained	NULL
from	NULL
untreated	NULL
M2-AML	NULL
blast	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
,	NULL
Lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
it	NULL
is	NULL
not	NULL
modulated	NULL
after	NULL
12	NULL
h	NULL
of	NULL
ATRA	NULL
or	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
,	NULL
Lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
RARa	NULL
protein	NULL
expression	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
NEs	NULL
obtained	NULL
from	NULL
the	NULL
other	NULL
types	NULL
of	NULL
AML	NULL
blast	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

110	NULL
Cells	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
CD45	NULL
,	NULL
CD14	NULL
,	NULL
and	NULL
CD11b	NULL
expression	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
for	NULL
5	NULL
days	NULL
or	NULL
left	NULL
untreated	NULL
.	NULL

Peak	NULL
1	NULL
corresponds	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
CD11b	NULL
,	NULL
peak	NULL
2	NULL
corresponds	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
CD14	NULL
,	NULL
and	NULL
peak	NULL
3	NULL
corresponds	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
CD45	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
markers	NULL
listed	NULL
above	NULL
has	NULL
been	NULL
evaluated	NULL
in	NULL
proliferating	NULL
Kasumi-1	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
and	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
treated	NULL
with	NULL
ATRA	NULL
(	NULL
B	NULL
)	NULL
or	NULL
VD	NULL
(	NULL
C	NULL
)	NULL
,	NULL
in	NULL
proliferating	NULL
HL-60	NULL
cells	NULL
(	NULL
D	NULL
)	NULL
,	NULL
and	NULL
in	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
ATRA	NULL
(	NULL
E	NULL
)	NULL
or	NULL
VD	NULL
(	NULL
F	NULL
)	NULL
.	NULL

of	NULL
Number	NULL
Differentiation	NULL
Effects	NULL
of	NULL
ATRA	NULL
and	NULL
VD	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
Cells	NULL
.	NULL

To	NULL
better	NULL
characterize	NULL
ATRA-induced	NULL
monocytic	NULL
differentiation	NULL
of	NULL
M2	NULL
blast	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
compared	NULL
the	NULL
differentiation	NULL
capacity	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
derived	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
M2-AML	NULL
(	NULL
28	NULL
)	NULL
with	NULL
the	NULL
well-known	NULL
differentiation	NULL
capacity	NULL
of	NULL
HL-60	NULL
cells	NULL
(	NULL
M2/M3-AML	NULL
)	NULL
after	NULL
5	NULL
days	NULL
of	NULL
treatment	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
.	NULL

Morphological	NULL
analysis	NULL
performed	NULL
on	NULL
differentiated	NULL
cells	NULL
shows	NULL
that	NULL
only	NULL
monocytic	NULL
differentiation	NULL
can	NULL
be	NULL
induced	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
with	NULL
both	NULL
inducers	NULL
,	NULL
whereas	NULL
HL-60	NULL
cells	NULL
differentiate	NULL
to	NULL
monocytes	NULL
when	NULL
treated	NULL
with	NULL
VD	NULL
and	NULL
differentiate	NULL
to	NULL
granulocytes	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
was	NULL
confirmed	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
surface	NULL
marker	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
a	NULL
clear	NULL
induction	NULL
of	NULL
CD11b	NULL
and	NULL
CD14	NULL
expression	NULL
(	NULL
peak	NULL
I	NULL
and	NULL
peak	NULL
2	NULL
,	NULL
respectively	NULL
)	NULL
is	NULL
observed	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
after	NULL
treatment	NULL
with	NULL
ATRA	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
or	NULL
with	NULL
VD	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
,	NULL
even	NULL
if	NULL
a	NULL
bimodal	NULL
distribution	NULL
of	NULL
CD14/CD11b	NULL
expression	NULL
is	NULL
observed	NULL
,	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
negative	NULL
cells	NULL
.	NULL

Despite	NULL
this	NULL
observa-tion	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
differentiate	NULL
upon	NULL
ATRA	NULL
and	NULL
VD	NULL
treatment	NULL
.	NULL

HL-60	NULL
cells	NULL
express	NULL
only	NULL
CD11b	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

46	NULL
)	NULL
and	NULL
coexpress	NULL
CD14	NULL
and	NULL
CD11b	NULL
after	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4F	NULL
)	NULL
.	NULL

A	NULL
high	NULL
expression	NULL
level	NULL
of	NULL
CD45	NULL
is	NULL
evident	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
before	NULL
and	NULL
after	NULL
treatment	NULL
with	NULL
the	NULL
differentiation	NULL
inducers	NULL
(	NULL
Fig	NULL
.	NULL

4A-F	NULL
,	NULL
peak	NULL
3	NULL
)	NULL
.	NULL

VDR	NULL
and	NULL
RARa	NULL
Expression	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
Cells	NULL
before	NULL
and	NULL
after	NULL
12	NULL
h	NULL
of	NULL
ATRA	NULL
or	NULL
VD	NULL
Treatment	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
reveals	NULL
immunoreactive	NULL
RARa	NULL
bands	NULL
in	NULL
the	NULL
NEs	NULL
of	NULL
both	NULL
cell	NULL
lines	NULL
before	NULL
and	NULL
after	NULL
treatment	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
,	NULL
Lanes	NULL
1-6	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
ATRA	NULL
treatment	NULL
is	NULL
not	NULL
crucial	NULL
for	NULL
RARa	NULL
detection	NULL
.	NULL

The	NULL
apparent	NULL
molecular	NULL
weight	NULL
of	NULL
this	NULL
nuclear	NULL
receptor	NULL
is	NULL
not	NULL
homogeneous	NULL
in	NULL
the	NULL
two	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

Because	NULL
RARa	NULL
is	NULL
a	NULL
phospho-protein	NULL
,	NULL
the	NULL
size	NULL
variability	NULL
ranging	NULL
from	NULL
M	NULL
,	NULL
54,000	NULL
to	NULL
M	NULL
,	NULL
58,000	NULL
is	NULL
probably	NULL
due	NULL
to	NULL
different	NULL
levels	NULL
of	NULL
phosphorylation	NULL
(	NULL
64	NULL
)	NULL
.	NULL

Two	NULL
main	NULL
RARa	NULL
bands	NULL
are	NULL
detected	NULL
in	NULL
proliferating	NULL
and	NULL
ATRA-treated	NULL
Kasumi-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
,	NULL
Lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
and	NULL
only	NULL
one	NULL
band	NULL
of	NULL
M	NULL
,	NULL
58,000	NULL
110	NULL
Â©	NULL
A	NULL
8	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

16	NULL
:	NULL
It	NULL
10	NULL
>	NULL
3806	NULL
The	NULL
Fluorescence	NULL
Intensity	NULL
MONOCYTIC	NULL
DIFFERENTIATION	NULL
OF	NULL
AML-M2	NULL
BLAST	NULL
CELLS	NULL
C	NULL
=	NULL
9	NULL
-	NULL
<	NULL
I	NULL
E	NULL
XL	NULL
5	NULL
9	NULL
=	NULL
S	NULL
S	NULL
>	NULL
a	NULL
a	NULL
a	NULL
8	NULL
8	NULL
Â©	NULL
2	NULL
<	NULL
â¬C	NULL
\	NULL
<	NULL
TO	NULL
U	NULL
_	NULL
-	NULL
_	NULL
Â¥	NULL
xy	NULL
xyÂ¥	NULL
TI	NULL
IC	NULL
TI	NULL
A	NULL
ole	NULL
teal	NULL
~	NULL
-	NULL
>	NULL
-58	NULL
kDa	NULL
hare	NULL
mall	NULL
|-54	NULL
kDa	NULL
B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
RARa	NULL
and	NULL
VDR	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
RARa	NULL
protein	NULL
expression	NULL
in	NULL
NEs	NULL
from	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

B	NULL
,	NULL
VDR	NULL
protein	NULL
expression	NULL
in	NULL
NEs	NULL
from	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

Lane	NULL
J	NULL
,	NULL
proliferating	NULL
Kasumi-1	NULL
cells	NULL
;	NULL
Lane	NULL
2	NULL
,	NULL
Kasumi-1	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
;	NULL
Lane	NULL
3	NULL
,	NULL
Kasumi-1	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
VD	NULL
;	NULL
Lane	NULL
4	NULL
,	NULL
proliferating	NULL
HL-60	NULL
cells	NULL
;	NULL
Lane	NULL
5	NULL
,	NULL
HL-60	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
;	NULL
Lane	NULL
6	NULL
,	NULL
HL-60	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
VD	NULL
.	NULL

Estimated	NULL
molecular	NULL
masses	NULL
of	NULL
RARa	NULL
and	NULL
VDR	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
right	NULL
side	NULL
of	NULL
each	NULL
panel	NULL
.	NULL

is	NULL
detected	NULL
in	NULL
VD-treated	NULL
Kasumi-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
,	NULL
Lane	NULL
3	NULL
)	NULL
,	NULL
whereas	NULL
in	NULL
HL-60	NULL
cells	NULL
,	NULL
only	NULL
a	NULL
M	NULL
,	NULL
54,000	NULL
band	NULL
is	NULL
evident	NULL
with	NULL
both	NULL
inducers	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
Lanes	NULL
4-6	NULL
)	NULL
.	NULL

VD	NULL
treatment	NULL
is	NULL
crucial	NULL
for	NULL
VDR	NULL
detection	NULL
because	NULL
NEs	NULL
obtained	NULL
from	NULL
untreated	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
do	NULL
not	NULL
show	NULL
the	NULL
receptor	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
Lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
.	NULL

VDR	NULL
is	NULL
clearly	NULL
observed	NULL
in	NULL
the	NULL
NEs	NULL
of	NULL
both	NULL
cell	NULL
lines	NULL
after	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
Lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
.	NULL

In	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
a	NULL
clear	NULL
VDR	NULL
band	NULL
is	NULL
evident	NULL
in	NULL
the	NULL
NEs	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
Lane	NULL
2	NULL
)	NULL
.	NULL

This	NULL
result	NULL
is	NULL
superimposable	NULL
to	NULL
that	NULL
obtained	NULL
in	NULL
spontaneous	NULL
M2-AML	NULL
blast	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
ATRA-treated	NULL
HL-60	NULL
cells	NULL
,	NULL
in	NULL
keeping	NULL
with	NULL
the	NULL
results	NULL
described	NULL
for	NULL
M3	NULL
spontaneous	NULL
blast	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
,	NULL
do	NULL
not	NULL
show	NULL
any	NULL
increase	NULL
of	NULL
VDR	NULL
abundance	NULL
in	NULL
the	NULL
nuclear	NULL
compartment	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
Lane	NULL
5	NULL
)	NULL
.	NULL

To	NULL
clarify	NULL
whether	NULL
the	NULL
VDR	NULL
induction	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
could	NULL
depend	NULL
on	NULL
transcriptional	NULL
regulation	NULL
by	NULL
ATRA	NULL
,	NULL
we	NULL
performed	NULL
RT-PCR	NULL
analysis	NULL
on	NULL
the	NULL
VDR	NULL
primary	NULL
transcript	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
before	NULL
and	NULL
after	NULL
the	NULL
differentiation	NULL
induction	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
it	NULL
has	NULL
been	NULL
recently	NULL
described	NULL
that	NULL
a	NULL
functional	NULL
RARE	NULL
is	NULL
present	NULL
in	NULL
intron	NULL
1C	NULL
of	NULL
the	NULL
VDR	NULL
gene	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
clearly	NULL
indicate	NULL
that	NULL
in	NULL
both	NULL
cellular	NULL
contexts	NULL
,	NULL
VDR	NULL
primary	NULL
transcript	NULL
is	NULL
detectable	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
suggesting	NULL
that	NULL
VDR	NULL
protein	NULL
expression	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
is	NULL
not	NULL
due	NULL
to	NULL
transcriptional	NULL
regulation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DNA	NULL
Binding	NULL
Activity	NULL
of	NULL
VDR	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
Cells	NULL
.	NULL

Because	NULL
Kasumi-1	NULL
cells	NULL
are	NULL
induced	NULL
to	NULL
monocytic	NULL
differentiation	NULL
both	NULL
with	NULL
ATRA	NULL
and	NULL
VD	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
ability	NULL
of	NULL
VDR	NULL
,	NULL
which	NULL
is	NULL
present	NULL
in	NULL
the	NULL
NEs	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
to	NULL
bind	NULL
a	NULL
DR3-type	NULL
VDRE	NULL
in	NULL
EMSA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
Lanes	NULL
2	NULL
and	NULL
5	NULL
,	NULL
in	NULL
untreated	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
a	NULL
major	NULL
complex	NULL
is	NULL
detected	NULL
,	NULL
even	NULL
if	NULL
the	NULL
band	NULL
intensity	NULL
is	NULL
lower	NULL
than	NULL
that	NULL
in	NULL
VD-	NULL
or	NULL
ATRA-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
Lanes	NULL
8	NULL
and	NULL
11	NULL
;	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
Lanes	NULL
14	NULL
and	NULL
17	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
certainly	NULL
contains	NULL
RXRa	NULL
because	NULL
a	NULL
clear	NULL
supershifted	NULL
band	NULL
is	NULL
detected	NULL
with	NULL
the	NULL
anti-RXR	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
Lanes	NULL
4	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Very	NULL
little	NULL
or	NULL
no	NULL
RARa	NULL
and	NULL
VDR	NULL
are	NULL
present	NULL
in	NULL
the	NULL
complex	NULL
because	NULL
it	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
anti-RARa	NULL
or	NULL
anti-	NULL
VDR	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
,	NULL
compare	NULL
Lanes	NULL
2	NULL
and	NULL
3	NULL
and	NULL
Lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

After	NULL
12	NULL
h	NULL
of	NULL
treatment	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
,	NULL
VDR	NULL
is	NULL
clearly	NULL
detected	NULL
in	NULL
the	NULL
major	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
Lane	NULL
8	NULL
;	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
Lane	NULL
14	NULL
)	NULL
because	NULL
a	NULL
consistent	NULL
decrease	NULL
in	NULL
intensity	NULL
is	NULL
caused	NULL
by	NULL
the	NULL
VDR	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
Lane	NULL
12	NULL
;	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
Lane	NULL
15	NULL
)	NULL
.	NULL

No	NULL
supershift	NULL
of	NULL
the	NULL
major	NULL
complex	NULL
is	NULL
evident	NULL
in	NULL
Kasumi-1	NULL
NEs	NULL
after	NULL
VD	NULL
or	NULL
ATRA	NULL
treatment	NULL
,	NULL
when	NULL
they	NULL
are	NULL
matched	NULL
with	NULL
RARa	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
compare	NULL
Lanes	NULL
8	NULL
and	NULL
9	NULL
;	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
compare	NULL
Lanes	NULL
17	NULL
and	NULL
18	NULL
)	NULL
.	NULL

After	NULL
VD	NULL
and	NULL
ATRA	NULL
treatment	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
the	NULL
NEs	NULL
showed	NULL
an	NULL
increased	NULL
abundance	NULL
of	NULL
RXR	NULL
because	NULL
an	NULL
increased	NULL
intensity	NULL
of	NULL
the	NULL
supershifted	NULL
band	NULL
is	NULL
detected	NULL
with	NULL
the	NULL
RXR	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
Lanes	NULL
10	NULL
and	NULL
13	NULL
;	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
Lanes	NULL
16	NULL
and	NULL
19	NULL
)	NULL
.	NULL

These	NULL
data	NULL
clearly	NULL
show	NULL
that	NULL
in	NULL
ATRA-	NULL
or	NULL
VD-treated	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
VDR	NULL
can	NULL
heterodimerize	NULL
with	NULL
RXR	NULL
and	NULL
efficiently	NULL
bind	NULL
to	NULL
the	NULL
DR3-responsive	NULL
element	NULL
.	NULL

In	NULL
HL-60	NULL
cells	NULL
,	NULL
on	NULL
the	NULL
contrary	NULL
,	NULL
a	NULL
VDR-containing	NULL
bandshift	NULL
complex	NULL
is	NULL
observed	NULL
only	NULL
after	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

6E	NULL
,	NULL
compare	NULL
Lanes	NULL
30	NULL
and	NULL
31	NULL
)	NULL
and	NULL
not	NULL
upon	NULL
ATRA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

6F	NULL
,	NULL
compare	NULL
Lanes	NULL
36	NULL
and	NULL
37	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
VDR-VDRE	NULL
complex	NULL
formation	NULL
is	NULL
greatly	NULL
enhanced	NULL
by	NULL
VD	NULL
or	NULL
ATRA	NULL
treatment	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
even	NULL
if	NULL
we	NULL
can	NULL
not	NULL
exclude	NULL
that	NULL
a	NULL
ligand-independent	NULL
complex	NULL
might	NULL
be	NULL
present	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
compare	NULL
Lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

vo	NULL
ATRA	NULL
r	NULL
tof	NULL
1	NULL
I	NULL
1	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
9	NULL
a	NULL
a	NULL
2	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
8	NULL
8	NULL
8	NULL
&	NULL
C	NULL
&	NULL
C	NULL
C	NULL
<	NULL
4	NULL
o	NULL
0	NULL
if	NULL
6	NULL
%	NULL
-	NULL
6	NULL
&	NULL
5	NULL
TE	NULL
CC	NULL
IC	NULL
>	NULL
C	NULL
CC	NULL
CC	NULL
>	NULL
C	NULL
>	NULL
C	NULL
CC	NULL
CC	NULL
oe	NULL
ie	NULL
a	NULL
+o	NULL
o	NULL
+	NULL
+	NULL
wow	NULL
w	NULL
W	NULL
wow	NULL
w	NULL
w	NULL
W	NULL
w	NULL
W	NULL
Wo	NULL
wow	NULL
w	NULL
W	NULL
W	NULL
w	NULL
O	NULL
2	NULL
Z	NULL
22	NULL
2	NULL
2	NULL
22	NULL
Z	NULL
Z	NULL
2	NULL
2	NULL
2	NULL
22	NULL
Z	NULL
ZZ	NULL
.	NULL

Â®	NULL
+	NULL
be	NULL
ks	NULL
be	NULL
vor/Rxr-	NULL
Â»	NULL
-	NULL
â	NULL
nu	NULL
â	NULL
W	NULL
-_	NULL
Wa	NULL
_	NULL
-vornxe	NULL
1	NULL
2	NULL
8	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
to	NULL
f	NULL
rds	NULL
t	NULL
d6	NULL
de	NULL
ir	NULL
is	NULL
to	NULL
A	NULL
B	NULL
c	NULL
UNTREATED	NULL
VD	NULL
ATRA	NULL
a	NULL
a	NULL
Pl	NULL
a	NULL
<	NULL
<	NULL
a	NULL
$	NULL
2	NULL
af	NULL
-	NULL
fe	NULL
#	NULL
s	NULL
0	NULL
$	NULL
e	NULL
as	NULL
&	NULL
c	NULL
coc	NULL
c	NULL
a	NULL
c	NULL
c	NULL
coc	NULL
a	NULL
g	NULL
&	NULL
i	NULL
SE	NULL
&	NULL
E	NULL
Sg	NULL
&	NULL
#	NULL
SE	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+o	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
o	NULL
#	NULL
4	NULL
8	NULL
%	NULL
3	NULL
Â¥	NULL
3	NULL
3	NULL
2	NULL
5	NULL
4	NULL
2	NULL
3	NULL
4	NULL
2	NULL
2	NULL
2	NULL
%	NULL
Â«	NULL
we	NULL
om	NULL
ge	NULL
am	NULL
nn	NULL
win	NULL
R	NULL
bs	NULL
bo	NULL
â	NULL
u	NULL
vorrrxa-	NULL
--	NULL
vor/rxa	NULL
did	NULL
bul	NULL
a	NULL
at	NULL
f	NULL
tt	NULL
t	NULL
t+	NULL
MD	NULL
...	NULL
...	NULL
2r	NULL
ze	NULL
zo	NULL
so	NULL
31	NULL
s2	NULL
as	NULL
se	NULL
35	NULL
ss	NULL
ar	NULL
38	NULL
D	NULL
E	NULL
F	NULL
20	NULL
21	NULL
22	NULL
23	NULL
24	NULL
25	NULL
26	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

EMSA	NULL
of	NULL
VDR	NULL
after	NULL
binding	NULL
to	NULL
a	NULL
DR3-type	NULL
DNA	NULL
element	NULL
in	NULL
NEs	NULL
of	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

NEs	NULL
from	NULL
untreated	NULL
,	NULL
VD-treated	NULL
(	NULL
12	NULL
h	NULL
)	NULL
,	NULL
or	NULL
ATRA-treated	NULL
(	NULL
12	NULL
h	NULL
)	NULL
Kasumi-1	NULL
cells	NULL
(	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
,	NULL
respectively	NULL
)	NULL
and	NULL
from	NULL
untreated	NULL
,	NULL
VD-treated	NULL
,	NULL
and	NULL
ATRA-treated	NULL
HL-60	NULL
cells	NULL
(	NULL
D	NULL
,	NULL
Â£	NULL
,	NULL
and	NULL
F	NULL
,	NULL
respectively	NULL
)	NULL
were	NULL
assayed	NULL
for	NULL
specific	NULL
binding	NULL
to	NULL
a	NULL
*P	NULL
-labeled	NULL
DR3-type	NULL
DNA	NULL
element	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
identity	NULL
of	NULL
nuclear	NULL
receptors	NULL
participating	NULL
in	NULL
the	NULL
shifted	NULL
complexes	NULL
,	NULL
antibodies	NULL
to	NULL
RARa	NULL
@	NULL
,	NULL
RXR	NULL
,	NULL
and	NULL
VDR	NULL
were	NULL
used	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
shifted	NULL
complexes	NULL
containing	NULL
VDR	NULL
and	NULL
RXR	NULL
.	NULL

3807	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

MONOCYTIC	NULL
DIFFERENTIATION	NULL
OF	NULL
AML-M2	NULL
BLAST	NULL
CELLS	NULL
Io	NULL
r	NULL
s	NULL
40	NULL
5006	NULL
7	NULL
s	NULL
9	NULL
o	NULL
no	NULL
or	NULL
pOSTEO/CaBPCAT	NULL
-=-	NULL
+	NULL
-	NULL
+0	NULL
-	NULL
+	NULL
Lo	NULL
ce	NULL
2	NULL
eR	NULL
R2	NULL
<	NULL
vit	NULL
.	NULL

D	NULL
-o-	NULL
-	NULL
-	NULL
4	NULL
+	NULL
oe	NULL
pTKRARE	NULL
ese	NULL
e	NULL
-	NULL
-	NULL
-	NULL
oo	NULL
ATRA	NULL
Roe	NULL
op	NULL
#	NULL
o-	NULL
-	NULL
se	NULL
owo	NULL
$	NULL
o	NULL
oe	NULL
se	NULL
C	NULL
D	NULL
pOSTEO/CaBPCAT	NULL
-	NULL
+	NULL
-	NULL
+	NULL
_-	NULL
-+	NULL
seme	NULL
al	NULL
oe	NULL
ke	NULL
oke	NULL
Vit	NULL
.	NULL

D	NULL
s-	NULL
w	NULL
in	NULL
ome	NULL
0	NULL
fe	NULL
Gk	NULL
Roe	NULL
o	NULL
$	NULL
0g	NULL
-	NULL
o-pTKRARE	NULL
mio	NULL
Wi	NULL
oen	NULL
cee	NULL
0	NULL
Wi	NULL
e	NULL
Lo	NULL
ap	NULL
oo	NULL
o	NULL
poo-ATRA	NULL
-o	NULL
e	NULL
ot	NULL
og	NULL
-	NULL
o-	NULL
moo	NULL
ow	NULL
om	NULL
%	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

CAT	NULL
assays	NULL
of	NULL
transfected	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

pOSTEO/CaBPCAT	NULL
(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
or	NULL
pTK/RAREB2-CAT	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
was	NULL
transfected	NULL
in	NULL
Kasumi-1	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
HL-60	NULL
(	NULL
C	NULL
and	NULL
DD	NULL
)	NULL
cells	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
for	NULL
48	NULL
h.	NULL
Amounts	NULL
of	NULL
cell	NULL
extracts	NULL
used	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
same	NULL
value	NULL
of	NULL
the	NULL
B-galactosidase	NULL
activity	NULL
.	NULL

Ability	NULL
of	NULL
Endogenous	NULL
VDR	NULL
to	NULL
Activate	NULL
Transcription	NULL
of	NULL
a	NULL
VDRE-dependent	NULL
Promoter	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
Cells	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
transactivation	NULL
capacity	NULL
of	NULL
endogenous	NULL
VDR	NULL
and	NULL
RAR	NULL
,	NULL
we	NULL
transiently	NULL
transfected	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
with	NULL
the	NULL
reporter	NULL
constructs	NULL
pOsteo/CaBP-CAT	NULL
and	NULL
pRAREB2/TK-CAT	NULL
and	NULL
then	NULL
treated	NULL
them	NULL
for	NULL
48	NULL
h	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
both	NULL
ATRA	NULL
treatment	NULL
and	NULL
VD	NULL
treatment	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
cause	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
pOsteo/CaBP-CAT	NULL
reporter	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
Lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
,	NULL
whereas	NULL
ATRA	NULL
treatment	NULL
but	NULL
not	NULL
VD	NULL
treatment	NULL
causes	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
pTK/RARERB2-CAT	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
Lanes	NULL
10	NULL
and	NULL
12	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
provides	NULL
further	NULL
evidence	NULL
that	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
ATRA	NULL
specifically	NULL
activates	NULL
transcription	NULL
through	NULL
a	NULL
VDRE	NULL
just	NULL
as	NULL
efficiently	NULL
as	NULL
VD	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
ATRA	NULL
on	NULL
VDRE-dependent	NULL
transcription	NULL
is	NULL
restricted	NULL
to	NULL
M2-type	NULL
blast	NULL
cells	NULL
because	NULL
no	NULL
transcriptional	NULL
activation	NULL
of	NULL
pOsteo/CaBP-CAT	NULL
is	NULL
evident	NULL
after	NULL
ATRA	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
,	NULL
Lane	NULL
16	NULL
)	NULL
;	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
reporter	NULL
activity	NULL
is	NULL
observed	NULL
only	NULL
after	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
,	NULL
Lane	NULL
18	NULL
)	NULL
.	NULL

The	NULL
pTK/RAREB2-CAT	NULL
construct	NULL
is	NULL
transactivated	NULL
quite	NULL
consistently	NULL
in	NULL
HL-60	NULL
cells	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
but	NULL
not	NULL
after	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

7D	NULL
,	NULL
Lanes	NULL
24	NULL
and	NULL
22	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
pOsteo/CaBP-CAT	NULL
activation	NULL
observed	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
after	NULL
ATRA	NULL
treatment	NULL
is	NULL
due	NULL
to	NULL
a	NULL
VDR	NULL
induction	NULL
.	NULL

Even	NULL
if	NULL
several	NULL
reports	NULL
indicate	NULL
that	NULL
a	NULL
VD-independent	NULL
transactivation	NULL
may	NULL
occur	NULL
mainly	NULL
in	NULL
kidney	NULL
and	NULL
intestine	NULL
epithelial	NULL
cells	NULL
(	NULL
65-67	NULL
)	NULL
,	NULL
pOsteo/CaBP-CAT	NULL
transactivation	NULL
observed	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
after	NULL
ATRA	NULL
treatment	NULL
seems	NULL
to	NULL
be	NULL
more	NULL
dependent	NULL
on	NULL
increased	NULL
VDR	NULL
nuclear	NULL
abundance	NULL
than	NULL
on	NULL
ligand-independent	NULL
activation	NULL
,	NULL
as	NULL
also	NULL
demonstrated	NULL
by	NULL
VDR	NULL
protein	NULL
expression	NULL
and	NULL
EMSA	NULL
experiments	NULL
.	NULL

Expression	NULL
of	NULL
ATRA	NULL
and	NULL
VD	NULL
Primary	NULL
Response	NULL
Genes	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
Cells	NULL
.	NULL

To	NULL
monitor	NULL
the	NULL
ability	NULL
of	NULL
ATRA	NULL
and	NULL
VD	NULL
to	NULL
activate	NULL
the	NULL
genetic	NULL
program	NULL
underlying	NULL
monocytic	NULL
differentiation	NULL
in	NULL
the	NULL
M2	NULL
cellular	NULL
context	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
expression	NULL
of	NULL
VD-responsive	NULL
genes	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
such	NULL
as	NULL
HMSE-1	NULL
,	NULL
CD14	NULL
,	NULL
and	NULL
hOC	NULL
by	NULL
RT-PCR	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
controlled	NULL
by	NULL
a	NULL
functional	NULL
VDRE	NULL
,	NULL
such	NULL
as	NULL
p21***	NULL
'	NULL
(	NULL
51	NULL
)	NULL
,	NULL
or	NULL
RARE	NULL
,	NULL
such	NULL
as	NULL
E3	NULL
(	NULL
52	NULL
)	NULL
,	NULL
IRF-1	NULL
(	NULL
53	NULL
)	NULL
and	NULL
p21	NULL
``	NULL
~*	NULL
``	NULL
(	NULL
68	NULL
)	NULL
,	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
after	NULL
different	NULL
times	NULL
of	NULL
ATRA	NULL
or	NULL
VD	NULL
treatment	NULL
.	NULL

Fig	NULL
.	NULL

8	NULL
shows	NULL
that	NULL
both	NULL
ATRA	NULL
and	NULL
VD	NULL
treatment	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
causes	NULL
a	NULL
rapid	NULL
induction	NULL
of	NULL
HMSE-1	NULL
,	NULL
CD14	NULL
,	NULL
and	NULL
hOC	NULL
expression	NULL
,	NULL
demonstrating	NULL
VDR	NULL
involvement	NULL
in	NULL
ATRA-dependent	NULL
monocytic	NULL
differentiation	NULL
of	NULL
M2-type	NULL
blast	NULL
cells	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
these	NULL
VD-responsive	NULL
genes	NULL
are	NULL
not	NULL
induced	NULL
in	NULL
ATRA-treated	NULL
HL-60	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
neither	NULL
VD	NULL
treatment	NULL
nor	NULL
ATRA	NULL
treatment	NULL
is	NULL
able	NULL
to	NULL
modify	NULL
the	NULL
expression	NULL
of	NULL
RA	NULL
primary	NULL
responsive	NULL
genes	NULL
,	NULL
such	NULL
as	NULL
E3	NULL
and	NULL
IRF-1	NULL
,	NULL
that	NULL
are	NULL
constitutively	NULL
expressed	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
no	NULL
induction	NULL
of	NULL
granulocytic	NULL
differentiation	NULL
occurs	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
same	NULL
analysis	NULL
performed	NULL
on	NULL
HL-60	NULL
cells	NULL
shows	NULL
a	NULL
rapid	NULL
induction	NULL
of	NULL
E3	NULL
and	NULL
IRF-1	NULL
expression	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
as	NULL
expected	NULL
.	NULL

Despite	NULL
the	NULL
differential	NULL
phenotypic	NULL
effect	NULL
observed	NULL
in	NULL
HL-60	NULL
cells	NULL
KASUMI-1	NULL
ATRA	NULL
VD	NULL
NEG	NULL
.	NULL

CONTROL	NULL
HL	NULL
60	NULL
HL	NULL
60	NULL
ATRA	NULL
HL	NULL
60	NULL
VD	NULL
T	NULL
p3	NULL
2	NULL
<	NULL
N2	NULL
HMSE-1	NULL
hOC	NULL
CD	NULL
14	NULL
Bam	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

Detection	NULL
by	NULL
RT-PCR	NULL
of	NULL
HMSE-1	NULL
,	NULL
hOC	NULL
,	NULL
and	NULL
CD14	NULL
mRNAs	NULL
in	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
or	NULL
left	NULL
untreated	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
proliferating	NULL
Kasumi-1	NULL
cells	NULL
;	NULL
Lane	NULL
2	NULL
,	NULL
Kasumi-1	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
;	NULL
Lane	NULL
3	NULL
,	NULL
Kasumi-1	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
VD	NULL
;	NULL
Lane	NULL
4	NULL
,	NULL
proliferating	NULL
HL-60	NULL
cells	NULL
;	NULL
Lane	NULL
5	NULL
,	NULL
HL-60	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
ATRA	NULL
;	NULL
Lane	NULL
6	NULL
,	NULL
HL-60	NULL
cells	NULL
treated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
VD	NULL
;	NULL
Lane	NULL
7	NULL
,	NULL
negative	NULL
control	NULL
performed	NULL
without	NULL
the	NULL
cDNA	NULL
template	NULL
.	NULL

RT-PCR	NULL
products	NULL
of	NULL
82m	NULL
mRNA	NULL
are	NULL
shown	NULL
in	NULL
the	NULL
bottom	NULL
panel	NULL
.	NULL

3808	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

MONOCYTIC	NULL
DIFFERENTIATION	NULL
OF	NULL
AML-M2	NULL
BLAST	NULL
CELLS	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
treatment	NULL
,	NULL
p21***	NULL
'	NULL
expression	NULL
is	NULL
induced	NULL
after	NULL
1	NULL
h	NULL
by	NULL
both	NULL
differentiating	NULL
agents	NULL
,	NULL
suggesting	NULL
that	NULL
its	NULL
expression	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
induce	NULL
monocytic	NULL
differentiation	NULL
,	NULL
as	NULL
suggested	NULL
recently	NULL
(	NULL
51	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
the	NULL
constitutively	NULL
expressed	NULL
B2m	NULL
mRNA	NULL
was	NULL
assessed	NULL
to	NULL
monitor	NULL
RNA	NULL
abundance	NULL
in	NULL
all	NULL
samples	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
Lanes	NULL
1-6	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Differentiation	NULL
of	NULL
AML	NULL
blast	NULL
cells	NULL
is	NULL
blocked	NULL
at	NULL
different	NULL
levels	NULL
of	NULL
maturation	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
French-	NULL
classification	NULL
(	NULL
29	NULL
)	NULL
and	NULL
the	NULL
immunological	NULL
classification	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Blast	NULL
cells	NULL
maintain	NULL
the	NULL
capacity	NULL
to	NULL
divide	NULL
,	NULL
but	NULL
the	NULL
rate	NULL
of	NULL
cell	NULL
division	NULL
decreases	NULL
progressively	NULL
as	NULL
blast	NULL
cells	NULL
undergo	NULL
a	NULL
series	NULL
of	NULL
differentiation	NULL
transi-tions	NULL
.	NULL

The	NULL
consequence	NULL
of	NULL
this	NULL
biological	NULL
behavior	NULL
is	NULL
that	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
leukemic	NULL
blast	NULL
cells	NULL
are	NULL
arrested	NULL
in	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
and	NULL
,	NULL
despite	NULL
the	NULL
expression	NULL
of	NULL
cyclin-dependent	NULL
inhibitors	NULL
,	NULL
never	NULL
reach	NULL
spontaneous	NULL
terminal	NULL
differentiation	NULL
(	NULL
1	NULL
,	NULL
2	NULL
,	NULL
69	NULL
)	NULL
.	NULL

Differentiation	NULL
induction	NULL
therapy	NULL
based	NULL
on	NULL
treatment	NULL
with	NULL
hemopoietic	NULL
growth	NULL
factors	NULL
such	NULL
as	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
or	NULL
monocyte	NULL
colony-stimulating	NULL
factor	NULL
is	NULL
inefficient	NULL
because	NULL
blast	NULL
cells	NULL
are	NULL
not	NULL
responsive	NULL
to	NULL
these	NULL
cytokines	NULL
,	NULL
despite	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
corresponding	NULL
receptors	NULL
(	NULL
16-18	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
experiments	NULL
indicate	NULL
that	NULL
these	NULL
hematopoietic	NULL
growth	NULL
factors	NULL
are	NULL
more	NULL
efficient	NULL
in	NULL
recruiting	NULL
blast	NULL
cells	NULL
to	NULL
the	NULL
proliferative	NULL
pathway	NULL
than	NULL
to	NULL
the	NULL
differentiative	NULL
pathway	NULL
(	NULL
70	NULL
)	NULL
.	NULL

Efficacy	NULL
of	NULL
differentiation	NULL
therapy	NULL
based	NULL
on	NULL
ATRA	NULL
has	NULL
been	NULL
demonstrated	NULL
only	NULL
in	NULL
APL	NULL
blast	NULL
cells	NULL
(	NULL
9	NULL
,	NULL
10	NULL
,	NULL
71	NULL
)	NULL
.	NULL

Because	NULL
differentiation	NULL
therapy	NULL
with	NULL
physiological	NULL
inducers	NULL
is	NULL
a	NULL
highly	NULL
attractive	NULL
approach	NULL
to	NULL
control	NULL
leukemic	NULL
cell	NULL
growth	NULL
(	NULL
72	NULL
)	NULL
,	NULL
we	NULL
have	NULL
evaluated	NULL
the	NULL
capacity	NULL
of	NULL
ATRA	NULL
and	NULL
VD	NULL
to	NULL
induce	NULL
myeloid	NULL
differentiation	NULL
in	NULL
different	NULL
types	NULL
of	NULL
AML	NULL
blast	NULL
cells	NULL
.	NULL

We	NULL
found	NULL
that	NULL
spontaneous	NULL
M2-type	NULL
AML	NULL
blast	NULL
cells	NULL
,	NULL
independent	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
,	NULL
are	NULL
induced	NULL
to	NULL
monocytic	NULL
differentiation	NULL
with	NULL
either	NULL
ATRA	NULL
treatment	NULL
or	NULL
VD	NULL
treatment	NULL
.	NULL

Spontaneous	NULL
MO/M1	NULL
blast	NULL
cells	NULL
are	NULL
not	NULL
responsive	NULL
to	NULL
these	NULL
inducers	NULL
.	NULL

M3-type	NULL
AML	NULL
blast	NULL
cells	NULL
,	NULL
as	NULL
already	NULL
described	NULL
,	NULL
are	NULL
responsive	NULL
only	NULL
to	NULL
ATRA	NULL
,	NULL
and	NULL
not	NULL
to	NULL
VD	NULL
.	NULL

Our	NULL
original	NULL
observation	NULL
is	NULL
that	NULL
VDR	NULL
protein	NULL
is	NULL
detected	NULL
after	NULL
ATRA	NULL
treatment	NULL
in	NULL
the	NULL
nuclear	NULL
compartment	NULL
of	NULL
M2	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
the	NULL
NEs	NULL
of	NULL
MO/M1	NULL
and	NULL
M3	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
both	NULL
ATRA	NULL
and	NULL
VD	NULL
are	NULL
able	NULL
to	NULL
increase	NULL
the	NULL
nuclear	NULL
abundance	NULL
of	NULL
VDR	NULL
in	NULL
M2-type	NULL
blast	NULL
cells	NULL
.	NULL

To	NULL
gain	NULL
some	NULL
insight	NULL
into	NULL
the	NULL
molecular	NULL
mechanism	NULL
underlying	NULL
monocytic	NULL
differentiation	NULL
induced	NULL
by	NULL
ATRA	NULL
in	NULL
M2-AML	NULL
blast	NULL
cells	NULL
,	NULL
we	NULL
studied	NULL
VDR	NULL
and	NULL
RARa	NULL
expression	NULL
and	NULL
VDR	NULL
function	NULL
in	NULL
two	NULL
AML	NULL
cell	NULL
lines	NULL
:	NULL
(	NULL
a	NULL
)	NULL
Kasumi-1	NULL
(	NULL
M2-type	NULL
cell	NULL
line	NULL
)	NULL
;	NULL
and	NULL
(	NULL
b	NULL
)	NULL
HL-60	NULL
(	NULL
M2/M3-type	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

Kasumi-1	NULL
cells	NULL
are	NULL
representative	NULL
of	NULL
spontaneous	NULL
M2-AML	NULL
blast	NULL
cells	NULL
because	NULL
only	NULL
monocytic	NULL
differentiation	NULL
is	NULL
achieved	NULL
by	NULL
ATRA	NULL
or	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

HL-60	NULL
cells	NULL
are	NULL
a	NULL
classical	NULL
model	NULL
of	NULL
myeloid	NULL
maturation	NULL
because	NULL
they	NULL
differentiate	NULL
to	NULL
granulocytes	NULL
or	NULL
monocytes	NULL
when	NULL
treated	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
;	NULL
Ref	NULL
.	NULL

35	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
nuclear	NULL
VDR	NULL
protein	NULL
is	NULL
detected	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
after	NULL
either	NULL
ATRA	NULL
or	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
VDR	NULL
is	NULL
functionally	NULL
active	NULL
in	NULL
this	NULL
cellular	NULL
context	NULL
because	NULL
it	NULL
is	NULL
capable	NULL
of	NULL
binding	NULL
a	NULL
DR3	NULL
oligonucleotide	NULL
after	NULL
heterodimerization	NULL
with	NULL
RXR	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
and	NULL
activating	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
transfected	NULL
pOsteo/CaBP-CAT	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
obtained	NULL
in	NULL
HL-60	NULL
cells	NULL
after	NULL
VD	NULL
treatment	NULL
,	NULL
but	NULL
not	NULL
after	NULL
ATRA	NULL
treatment	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
ATRA	NULL
can	NULL
transactivate	NULL
the	NULL
pTK/RAREB2-CAT	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
in	NULL
HL-60	NULL
cells	NULL
and	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
RARa	NULL
is	NULL
functionally	NULL
active	NULL
in	NULL
both	NULL
cellular	NULL
contexts	NULL
.	NULL

Recent	NULL
reports	NULL
indicate	NULL
that	NULL
there	NULL
is	NULL
a	NULL
cross-over	NULL
of	NULL
the	NULL
nuclear	NULL
signaling	NULL
pathways	NULL
of	NULL
RA	NULL
and	NULL
VD	NULL
,	NULL
but	NULL
it	NULL
is	NULL
still	NULL
unclear	NULL
whether	NULL
the	NULL
interplay	NULL
between	NULL
the	NULL
different	NULL
nuclear	NULL
receptors	NULL
can	NULL
activate	NULL
different	NULL
signaling	NULL
pathways	NULL
during	NULL
hematopoietic	NULL
differentiation	NULL
(	NULL
73-75	NULL
)	NULL
.	NULL

The	NULL
peculiarity	NULL
of	NULL
our	NULL
results	NULL
is	NULL
that	NULL
both	NULL
ATRA	NULL
and	NULL
VD	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
monocytic	NULL
differentiation	NULL
in	NULL
M2-type	NULL
blast	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
described	NULL
ATRA-induced	NULL
pOsteo/CaBP-CAT	NULL
transactivation	NULL
is	NULL
also	NULL
obtained	NULL
with	NULL
compounds	NULL
such	NULL
as	NULL
8-bromo-cyclic	NULL
AMP	NULL
(	NULL
67	NULL
)	NULL
and	NULL
okadaic	NULL
acid	NULL
(	NULL
66	NULL
,	NULL
67	NULL
)	NULL
,	NULL
which	NULL
are	NULL
known	NULL
to	NULL
induce	NULL
a	NULL
VD-independent	NULL
,	NULL
VDR-mediated	NULL
transactivation	NULL
of	NULL
reporter	NULL
genes	NULL
(	NULL
65	NULL
)	NULL
.	NULL

This	NULL
transcription	NULL
activation	NULL
is	NULL
achieved	NULL
through	NULL
a	NULL
modulation	NULL
of	NULL
VDR	NULL
phosphorylation	NULL
levels	NULL
and	NULL
does	NULL
not	NULL
involve	NULL
a	NULL
VDR	NULL
protein	NULL
expression	NULL
induction	NULL
(	NULL
67	NULL
)	NULL
,	NULL
which	NULL
is	NULL
,	NULL
conversely	NULL
,	NULL
clearly	NULL
observed	NULL
in	NULL
ATRA-treated	NULL
Kasumi-1	NULL
cells	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
formation	NULL
of	NULL
spontaneous	NULL
VD-independent	NULL
complexes	NULL
between	NULL
endogenous	NULL
VDR-RXR	NULL
het-erodimers	NULL
and	NULL
genomic	NULL
DNA	NULL
can	NULL
probably	NULL
be	NULL
hypothesized	NULL
only	NULL
for	NULL
tissues	NULL
characterized	NULL
by	NULL
high	NULL
levels	NULL
of	NULL
VDR	NULL
nuclear	NULL
protein	NULL
expression	NULL
,	NULL
such	NULL
as	NULL
intestinal	NULL
epithelial	NULL
cells	NULL
(	NULL
65	NULL
)	NULL
.	NULL

The	NULL
existence	NULL
of	NULL
basal	NULL
VDR-RXR/DNA	NULL
interaction	NULL
complexes	NULL
is	NULL
unlikely	NULL
in	NULL
hematopoietic	NULL
cells	NULL
,	NULL
in	NULL
which	NULL
the	NULL
detection	NULL
of	NULL
significant	NULL
amounts	NULL
of	NULL
nuclear	NULL
VDR	NULL
protein	NULL
is	NULL
strictly	NULL
dependent	NULL
on	NULL
VD	NULL
treatment	NULL
(	NULL
23	NULL
)	NULL
.	NULL

We	NULL
can	NULL
thus	NULL
conclude	NULL
that	NULL
VDR-mediated	NULL
activation	NULL
of	NULL
gene	NULL
expression	NULL
induced	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
by	NULL
ATRA	NULL
probably	NULL
resides	NULL
on	NULL
mechanisms	NULL
that	NULL
are	NULL
not	NULL
strictly	NULL
related	NULL
to	NULL
VD-independent	NULL
transcription	NULL
activation	NULL
of	NULL
VDR	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
by	NULL
which	NULL
ATRA	NULL
induces	NULL
a	NULL
functionally	NULL
active	NULL
VDR	NULL
nuclear	NULL
protein	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
and	NULL
M2	NULL
blast	NULL
cells	NULL
are	NULL
still	NULL
unclear	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
VDR	NULL
gene	NULL
,	NULL
which	NULL
is	NULL
probably	NULL
RARE	NULL
dependent	NULL
(	NULL
46	NULL
)	NULL
,	NULL
is	NULL
activated	NULL
by	NULL
ATRA	NULL
in	NULL
both	NULL
Kasumi-1	NULL
and	NULL
HL-60	NULL
cells	NULL
because	NULL
a	NULL
primary	NULL
VDR	NULL
transcript	NULL
is	NULL
clearly	NULL
detectable	NULL
in	NULL
both	NULL
the	NULL
cellular	NULL
contexts	NULL
by	NULL
RT-PCR	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
ATRA-induced	NULL
VDR	NULL
expression	NULL
observed	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
is	NULL
not	NULL
strictly	NULL
regulated	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

Furthermore	NULL
,	NULL
VDR	NULL
expression	NULL
studies	NULL
in	NULL
spontaneous	NULL
leukemic	NULL
blast	NULL
cells	NULL
showed	NULL
a	NULL
discrepancy	NULL
between	NULL
VDR	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

VDR	NULL
mRNA	NULL
is	NULL
,	NULL
in	NULL
fact	NULL
,	NULL
detected	NULL
in	NULL
all	NULL
types	NULL
of	NULL
AML	NULL
blast	NULL
cells	NULL
before	NULL
VD	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

VDR	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
is	NULL
detected	NULL
in	NULL
the	NULL
nuclear	NULL
compartment	NULL
of	NULL
all	NULL
myeloid	NULL
blast	NULL
cells	NULL
only	NULL
after	NULL
VD	NULL
treatment	NULL
and	NULL
after	NULL
ATRA	NULL
treatment	NULL
of	NULL
M2-type	NULL
blast	NULL
cells	NULL
.	NULL

The	NULL
RARa	NULL
expression	NULL
pattern	NULL
is	NULL
different	NULL
because	NULL
both	NULL
mRNA	NULL
and	NULL
protein	NULL
are	NULL
detected	NULL
in	NULL
untreated	NULL
AML	NULL
blast	NULL
cells	NULL
,	NULL
and	NULL
protein	NULL
is	NULL
not	NULL
significantly	NULL
modulated	NULL
in	NULL
the	NULL
NEs	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
the	NULL
HL-60	NULL
and	NULL
Kasumi-1	NULL
leukemic	NULL
cell	NULL
lines	NULL
(	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
expression	NULL
studies	NULL
indicate	NULL
clearly	NULL
that	NULL
VDR	NULL
protein	NULL
abundance	NULL
in	NULL
untreated	NULL
leukemic	NULL
cells	NULL
is	NULL
very	NULL
low	NULL
,	NULL
and	NULL
that	NULL
after	NULL
VD	NULL
treatment	NULL
,	NULL
posttranscriptional	NULL
mechanisms	NULL
such	NULL
as	NULL
protein	NULL
stabilization	NULL
(	NULL
76	NULL
)	NULL
or	NULL
,	NULL
as	NULL
described	NULL
in	NULL
other	NULL
systems	NULL
,	NULL
increased	NULL
translation	NULL
efficiency	NULL
of	NULL
compartmentalized	NULL
mRNA	NULL
(	NULL
77	NULL
)	NULL
take	NULL
part	NULL
in	NULL
increasing	NULL
the	NULL
VDR	NULL
protein	NULL
abundance	NULL
in	NULL
the	NULL
nuclear	NULL
compartment	NULL
.	NULL

This	NULL
VDR	NULL
posttranscriptional	NULL
regulation	NULL
also	NULL
occurs	NULL
in	NULL
M2-type	NULL
blast	NULL
cells	NULL
after	NULL
ATRA	NULL
treatment	NULL
.	NULL

Both	NULL
ATRA	NULL
treatment	NULL
and	NULL
VD	NULL
treatment	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
rapidly	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
VD-responsive	NULL
genes	NULL
such	NULL
as	NULL
HMSE-1	NULL
,	NULL
CD14	NULL
,	NULL
and	NULL
hOC	NULL
.	NULL

These	NULL
data	NULL
clearly	NULL
demonstrate	NULL
that	NULL
VDR	NULL
is	NULL
involved	NULL
in	NULL
ATRA-dependent	NULL
monocytic	NULL
differentiation	NULL
of	NULL
M2-type	NULL
blast	NULL
cells	NULL
.	NULL

Moreover	NULL
,	NULL
these	NULL
VD-responsive	NULL
genes	NULL
are	NULL
not	NULL
induced	NULL
in	NULL
ATRA-treated	NULL
HL-60	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
neither	NULL
VD	NULL
treatment	NULL
nor	NULL
ATRA	NULL
treatment	NULL
is	NULL
able	NULL
to	NULL
modify	NULL
the	NULL
expression	NULL
of	NULL
RA	NULL
primary	NULL
responsive	NULL
genes	NULL
,	NULL
such	NULL
as	NULL
E3	NULL
and	NULL
IRF-1	NULL
,	NULL
which	NULL
are	NULL
constitutively	NULL
expressed	NULL
in	NULL
Kasumi-1	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
no	NULL
induction	NULL
of	NULL
granulocytic	NULL
differentiation	NULL
occurs	NULL
in	NULL
M2-type	NULL
blast	NULL
cells	NULL
,	NULL
even	NULL
if	NULL
RARa	NULL
is	NULL
expressed	NULL
and	NULL
is	NULL
functionally	NULL
active	NULL
in	NULL
transactivating	NULL
the	NULL
pTK/RARE/	NULL
B2-CAT	NULL
construct	NULL
.	NULL

The	NULL
same	NULL
analysis	NULL
performed	NULL
on	NULL
HL-60	NULL
cells	NULL
3809	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

MONOCYTIC	NULL
DIFFERENTIATION	NULL
OF	NULL
AML-M2	NULL
BLAST	NULL
CELLS	NULL
shows	NULL
a	NULL
rapid	NULL
induction	NULL
of	NULL
E3	NULL
and	NULL
IRF-1	NULL
expression	NULL
after	NULL
few	NULL
hours	NULL
of	NULL
ATRA	NULL
treatment	NULL
,	NULL
as	NULL
expected	NULL
.	NULL

Despite	NULL
the	NULL
differential	NULL
phenotypic	NULL
effect	NULL
observed	NULL
in	NULL
HL-60	NULL
cells	NULL
with	NULL
ATRA	NULL
or	NULL
VD	NULL
treatment	NULL
,	NULL
p21***	NULL
'	NULL
expression	NULL
is	NULL
induced	NULL
after	NULL
1	NULL
h	NULL
by	NULL
both	NULL
differentiating	NULL
agents	NULL
,	NULL
suggesting	NULL
that	NULL
its	NULL
expression	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
induce	NULL
monocytic	NULL
differentiation	NULL
,	NULL
as	NULL
suggested	NULL
recently	NULL
(	NULL
51	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
recent	NULL
report	NULL
showing	NULL
that	NULL
p21	NULL
``	NULL
**	NULL
``	NULL
expression	NULL
after	NULL
ATRA	NULL
treatment	NULL
is	NULL
associated	NULL
with	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
(	NULL
68	NULL
)	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
our	NULL
data	NULL
allow	NULL
us	NULL
to	NULL
hypothesize	NULL
that	NULL
the	NULL
M2	NULL
cellular	NULL
context	NULL
can	NULL
be	NULL
considered	NULL
a	NULL
differentiation	NULL
window	NULL
permissive	NULL
only	NULL
of	NULL
monocytic	NULL
differentiation	NULL
because	NULL
both	NULL
VD	NULL
and	NULL
ATRA	NULL
differentiation	NULL
inducers	NULL
are	NULL
capable	NULL
of	NULL
activating	NULL
this	NULL
differentiation	NULL
program	NULL
through	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
functional	NULL
nuclear	NULL
VDR	NULL
protein	NULL
.	NULL

This	NULL
observation	NULL
might	NULL
open	NULL
a	NULL
new	NULL
therapeutic	NULL
application	NULL
of	NULL
ATRA	NULL
,	NULL
even	NULL
if	NULL
the	NULL
response	NULL
of	NULL
AML	NULL
patients	NULL
(	NULL
including	NULL
M2-type	NULL
AML	NULL
)	NULL
to	NULL
treatment	NULL
with	NULL
this	NULL
differentiating	NULL
agent	NULL
remains	NULL
to	NULL
be	NULL
verified	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Nani	NULL
,	NULL
F.	NULL
,	NULL
Mars	NULL
,	NULL
W.	NULL
,	NULL
Kaczmarek	NULL
,	NULL
L.	NULL
,	NULL
Venturelli	NULL
,	NULL
D.	NULL
,	NULL
Anderson	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Calabretta	NULL
,	NULL
B	NULL
.	NULL

Expression	NULL
of	NULL
growth-regulated	NULL
genes	NULL
in	NULL
human	NULL
acute	NULL
leukemias	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
46	NULL
:	NULL
5162-5166	NULL
,	NULL
1986.	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Tagliafico	NULL
,	NULL
E.	NULL
,	NULL
Ceccherelli	NULL
,	NULL
G.	NULL
,	NULL
Selleri	NULL
,	NULL
L.	NULL
,	NULL
Calabretta	NULL
,	NULL
B.	NULL
,	NULL
Donelli	NULL
,	NULL
A.	NULL
,	NULL
Temperani	NULL
,	NULL
P.	NULL
,	NULL
Sarti	NULL
,	NULL
M.	NULL
,	NULL
Sacchi	NULL
,	NULL
S.	NULL
,	NULL
Emilia	NULL
,	NULL
G.	NULL
,	NULL
Torelli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Torelli	NULL
,	NULL
U	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
myeloperoxidase	NULL
gene	NULL
in	NULL
acute	NULL
and	NULL
chronic	NULL
myeloid	NULL
leukemias	NULL
:	NULL
relationship	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
cell	NULL
cycle-related	NULL
genes	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
3	NULL
:	NULL
423-430	NULL
,	NULL
1989.	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Manfredini	NULL
,	NULL
R.	NULL
,	NULL
Grande	NULL
,	NULL
A.	NULL
,	NULL
Torelli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Torelli	NULL
,	NULL
U	NULL
.	NULL

Proliferation	NULL
,	NULL
differentiation	NULL
arrest	NULL
,	NULL
and	NULL
survival	NULL
in	NULL
leukemic	NULL
blast	NULL
cells	NULL
.	NULL

Ann	NULL
.	NULL

N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
663	NULL
:	NULL
202-214	NULL
,	NULL
1992.	NULL
.	NULL

Torelli	NULL
,	NULL
U.	NULL
,	NULL
Ferrari	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Manfredini	NULL
,	NULL
R.	NULL
Proliferation	NULL
,	NULL
differentiation	NULL
and	NULL
pro	NULL
grammed	NULL
cell	NULL
death	NULL
:	NULL
an	NULL
outline	NULL
of	NULL
their	NULL
genetic	NULL
control	NULL
and	NULL
disorders	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
myelopoiesis	NULL
.	NULL

In	NULL
:	NULL
E.	NULL
Cacciola	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Deisserroth	NULL
,	NULL
and	NULL
R.	NULL
Giustolisi	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Hemopoictic	NULL
Growth	NULL
Factors	NULL
,	NULL
Oncogenes	NULL
and	NULL
Cytokines	NULL
in	NULL
Clinical	NULL
Hematology	NULL
,	NULL
pp	NULL
.	NULL

49-63	NULL
.	NULL

Basel	NULL
:	NULL
Basel	NULL
Karger	NULL
,	NULL
1994.	NULL
.	NULL

de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

The	NULL
1	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
fuses	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
gene	NULL
to	NULL
a	NULL
novel	NULL
transcribed	NULL
locus	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
347	NULL
:	NULL
558-561	NULL
,	NULL
1990.	NULL
.	NULL

Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Zangrilli	NULL
,	NULL
D.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Longo	NULL
,	NULL
L.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Giacomucci	NULL
,	NULL
A.	NULL
,	NULL
Rocchi	NULL
,	NULL
M.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Rambaldi	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Diverio	NULL
,	NULL
D.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Pelicci	NULL
,	NULL
P.G	NULL
.	NULL

Translocation	NULL
breakpoint	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
lies	NULL
within	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
locus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
:	NULL
1977-1981	NULL
,	NULL
1991.	NULL
.	NULL

Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Murty	NULL
,	NULL
V.	NULL
V.	NULL
,	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
Chromosomal	NULL
translocation	NULL
1	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
rar	NULL
a	NULL
with	NULL
a	NULL
novel	NULL
putative	NULL
transcription	NULL
factor	NULL
,	NULL
pml	NULL
.	NULL

Cell	NULL
,	NULL
66	NULL
:	NULL
663-674	NULL
,	NULL
1991.	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
De-Matteis	NULL
,	NULL
S.	NULL
,	NULL
Nervi	NULL
,	NULL
C.	NULL
,	NULL
Tomassoni	NULL
,	NULL
L.	NULL
,	NULL
Gelmetti	NULL
,	NULL
V.	NULL
,	NULL
Cioce	NULL
,	NULL
M.	NULL
,	NULL
Fanelli	NULL
,	NULL
M.	NULL
,	NULL
Ruthardt	NULL
,	NULL
M.	NULL
,	NULL
Ferrara	NULL
,	NULL
F.	NULL
F.	NULL
,	NULL
Zamir	NULL
,	NULL
L.	NULL
,	NULL
Seiser	NULL
,	NULL
C.	NULL
,	NULL
Lazar	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Minucci	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
Fusion	NULL
proteins	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor-a	NULL
recruit	NULL
histone	NULL
deacetylase	NULL
in	NULL
promyelocytic	NULL
leukaemia	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
397	NULL
:	NULL
815-818	NULL
,	NULL
1998.	NULL
.	NULL

Castaigne	NULL
,	NULL
S.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Ballerini	NULL
,	NULL
P.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
,	NULL
Fenaux	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Degos	NULL
,	NULL
L.	NULL
All-frans	NULL
retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
clinical	NULL
results	NULL
.	NULL

Blood	NULL
,	NULL
76	NULL
:	NULL
1704-1709	NULL
,	NULL
1990	NULL
.	NULL

Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Scheinberg	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Itri	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Hittelman	NULL
,	NULL
W.	NULL
N.	NULL
,	NULL
Vyas	NULL
,	NULL
R.	NULL
,	NULL
Andreeff	NULL
,	NULL
M.	NULL
,	NULL
Tafuri	NULL
,	NULL
A.	NULL
,	NULL
Jakubowski	NULL
,	NULL
A.	NULL
,	NULL
Gabrilove	NULL
,	NULL
S.	NULL
,	NULL
Gordon	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
Dmitrowsky	NULL
,	NULL
E.	NULL
Differentiation	NULL
therapy	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
tretinoin	NULL
(	NULL
all-frans-retinoic	NULL
acid	NULL
)	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
324	NULL
:	NULL
1385-1393	NULL
,	NULL
1991	NULL
.	NULL

Zeleznikle	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Nucifora	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Rowley	NULL
,	NULL
J.	NULL
D.	NULL
The	NULL
molecular	NULL
biology	NULL
of	NULL
myeloproliferative	NULL
disorders	NULL
as	NULL
revealed	NULL
by	NULL
chromosomal	NULL
abnormalities	NULL
.	NULL

Semin	NULL
.	NULL

Hematol	NULL
.	NULL

,	NULL
32	NULL
;	NULL
201-219	NULL
,	NULL
1995	NULL
.	NULL

Erickson	NULL
,	NULL
P.	NULL
,	NULL
Gao	NULL
,	NULL
J.	NULL
,	NULL
Chang	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Look	NULL
,	NULL
T.	NULL
,	NULL
Whisenant	NULL
,	NULL
E.	NULL
,	NULL
Raimondi	NULL
,	NULL
S.	NULL
,	NULL
Lasher	NULL
,	NULL
R.	NULL
,	NULL
Trujillo	NULL
,	NULL
J.	NULL
,	NULL
Rowley	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Drabkin	NULL
,	NULL
H.	NULL
Identification	NULL
of	NULL
breakpoints	NULL
in	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
and	NULL
isolation	NULL
of	NULL
a	NULL
fusion	NULL
transcript	NULL
,	NULL
amll/eto	NULL
,	NULL
with	NULL
similarity	NULL
to	NULL
Drosophila	NULL
segmentation	NULL
gene	NULL
,	NULL
runt	NULL
.	NULL

Blood	NULL
,	NULL
80	NULL
:	NULL
1825-1831	NULL
,	NULL
1992	NULL
.	NULL

Soekarman	NULL
,	NULL
D.	NULL
,	NULL
von	NULL
Lindern	NULL
,	NULL
M.	NULL
,	NULL
Daenen	NULL
,	NULL
S.	NULL
,	NULL
de	NULL
Jong	NULL
,	NULL
B.	NULL
,	NULL
Fonatsch	NULL
,	NULL
C.	NULL
,	NULL
Heinze	NULL
,	NULL
B.	NULL
,	NULL
Bartram	NULL
,	NULL
C.	NULL
,	NULL
Hagemeijer	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Grosveld	NULL
,	NULL
G.	NULL
The	NULL
translocation	NULL
(	NULL
6:9	NULL
)	NULL
(	NULL
p23	NULL
;	NULL
q34	NULL
)	NULL
shows	NULL
consistent	NULL
rearrangement	NULL
of	NULL
two	NULL
genes	NULL
and	NULL
defines	NULL
a	NULL
myeloproliferative	NULL
disorder	NULL
with	NULL
specific	NULL
clinical	NULL
features	NULL
.	NULL

Blood	NULL
,	NULL
79	NULL
:	NULL
2990-2997	NULL
,	NULL
1992	NULL
.	NULL

Nucifora	NULL
,	NULL
G.	NULL
,	NULL
Begy	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
Kobayashi	NULL
,	NULL
H.	NULL
,	NULL
Roulston	NULL
,	NULL
D.	NULL
,	NULL
Claxton	NULL
,	NULL
D.	NULL
,	NULL
Pedersenbjer-gaard	NULL
,	NULL
J.	NULL
,	NULL
Parganas	NULL
,	NULL
E.	NULL
,	NULL
Thle	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
and	NULL
Rowley	NULL
,	NULL
J.	NULL
D.	NULL
Consistent	NULL
intergenic	NULL
splicing	NULL
and	NULL
production	NULL
of	NULL
multiple	NULL
transcripts	NULL
between	NULL
AML1	NULL
at	NULL
21q22	NULL
and	NULL
unrelated	NULL
genes	NULL
at	NULL
3q26	NULL
in	NULL
(	NULL
321	NULL
)	NULL
(	NULL
q26q22	NULL
)	NULL
translocations	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
97	NULL
:	NULL
4004-4008	NULL
,	NULL
1994	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
Ferrucci	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
Testa	NULL
,	NULL
U.	NULL
,	NULL
Talamo	NULL
,	NULL
G.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Peschle	NULL
,	NULL
C.	NULL
,	NULL
Nicoletti	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
The	NULL
acute	NULL
promyelocytic	NULL
16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

3810	NULL
leukemia-specific	NULL
PML-RAR	NULL
a	NULL
fusion	NULL
protein	NULL
inhibits	NULL
differentiation	NULL
and	NULL
promotes	NULL
survival	NULL
of	NULL
myeloid	NULL
precursor	NULL
cells	NULL
.	NULL

Cell	NULL
,	NULL
74	NULL
:	NULL
423-431	NULL
,	NULL
1993	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Grande	NULL
,	NULL
A.	NULL
,	NULL
Manfredini	NULL
,	NULL
R.	NULL
,	NULL
Tagliafico	NULL
,	NULL
E.	NULL
,	NULL
Zucchini	NULL
,	NULL
P.	NULL
,	NULL
Torelli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Torelli	NULL
,	NULL
U	NULL
.	NULL

Expression	NULL
of	NULL
interleukins	NULL
1	NULL
,	NULL
3	NULL
,	NULL
6	NULL
,	NULL
stem	NULL
cell	NULL
factor	NULL
and	NULL
their	NULL
receptors	NULL
in	NULL
acute	NULL
leukemia	NULL
blast	NULL
cells	NULL
and	NULL
in	NULL
normal	NULL
peripheral	NULL
lymphocytes	NULL
and	NULL
monocytes	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
50	NULL
:	NULL
141-148	NULL
,	NULL
1993	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Grande	NULL
,	NULL
A.	NULL
,	NULL
Zucchini	NULL
,	NULL
P.	NULL
,	NULL
Manfredini	NULL
,	NULL
R.	NULL
,	NULL
Tagliafico	NULL
,	NULL
E.	NULL
,	NULL
Rossi	NULL
,	NULL
E.	NULL
,	NULL
Temperani	NULL
,	NULL
P.	NULL
,	NULL
Torelli	NULL
,	NULL
G.	NULL
,	NULL
Emilia	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Torelli	NULL
,	NULL
U.	NULL
Overexpression	NULL
of	NULL
c-kit	NULL
in	NULL
a	NULL
leukemic	NULL
cell	NULL
population	NULL
carrying	NULL
a	NULL
trisomy	NULL
4	NULL
and	NULL
its	NULL
relationship	NULL
with	NULL
the	NULL
proliferative	NULL
capacity	NULL
.	NULL

Leuk	NULL
.	NULL

Lymphoma	NULL
,	NULL
9	NULL
:	NULL
495-501	NULL
,	NULL
1993	NULL
.	NULL

Olsson	NULL
,	NULL
I.	NULL
,	NULL
Bergh	NULL
,	NULL
G.	NULL
,	NULL
Ehinger	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Gullberg	NULL
,	NULL
U	NULL
.	NULL

Cell	NULL
differentiation	NULL
in	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
.	NULL

Bur	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
57	NULL
:	NULL
1-16	NULL
,	NULL
1996	NULL
.	NULL

Estrov	NULL
,	NULL
Z.	NULL
,	NULL
Kurzrock	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Talpaz	NULL
,	NULL
M.	NULL
Cytokines	NULL
and	NULL
their	NULL
antagonists	NULL
in	NULL
myeloid	NULL
disorders	NULL
.	NULL

Semin	NULL
.	NULL

Hematol	NULL
.	NULL

,	NULL
32	NULL
:	NULL
220-231	NULL
,	NULL
1995	NULL
.	NULL

Sacchi	NULL
,	NULL
S.	NULL
,	NULL
Russo	NULL
,	NULL
D.	NULL
,	NULL
Avvisati	NULL
,	NULL
G.	NULL
,	NULL
Dastoli	NULL
,	NULL
G.	NULL
,	NULL
Lazzarino	NULL
,	NULL
M.	NULL
,	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Bonora	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Visani	NULL
,	NULL
G.	NULL
,	NULL
Grassi	NULL
,	NULL
C.	NULL
,	NULL
Tacona	NULL
,	NULL
L	NULL
,	NULL
Luzzi	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Vanzanelli	NULL
,	NULL
P.	NULL
All-frans	NULL
retinoic	NULL
acid	NULL
in	NULL
hematological	NULL
malignancies	NULL
,	NULL
an	NULL
update	NULL
.	NULL

GER	NULL
(	NULL
Gruppo	NULL
Ematologico	NULL
Retinoidi	NULL
)	NULL
.	NULL

Haematologica	NULL
,	NULL
82	NULL
:	NULL
106-121	NULL
,	NULL
1997	NULL
.	NULL

Studzinski	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
McLane	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Uskokovic	NULL
,	NULL
M.	NULL
R.	NULL
Signaling	NULL
pathways	NULL
for	NULL
vitamin	NULL
-induced	NULL
differentiation	NULL
:	NULL
implications	NULL
for	NULL
therapy	NULL
of	NULL
proliferative	NULL
and	NULL
neo-plastic	NULL
diseases	NULL
.	NULL

Crit	NULL
.	NULL

Rev	NULL
.	NULL

Eukaryotic	NULL
Gene	NULL
Expr	NULL
.	NULL

,	NULL
J	NULL
:	NULL
279-312	NULL
,	NULL
1993	NULL
.	NULL

Hsich	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Nakajima	NULL
,	NULL
S.	NULL
,	NULL
Galligan	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Jurutka	NULL
,	NULL
P.	NULL
W.	NULL
,	NULL
Haussler	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Whitfield	NULL
,	NULL
G.	NULL
K.	NULL
,	NULL
and	NULL
Haussler	NULL
,	NULL
M.	NULL
R.	NULL
Receptor	NULL
mediated	NULL
genomic	NULL
action	NULL
of	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
(	NULL
2	NULL
)	NULL
D-3	NULL
hormone	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
vitamin	NULL
D	NULL
receptor	NULL
in	NULL
Â£	NULL
.	NULL

colf	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
53	NULL
:	NULL
583-594	NULL
,	NULL
1995	NULL
.	NULL

Grande	NULL
,	NULL
A.	NULL
,	NULL
Manfredini	NULL
,	NULL
R.	NULL
,	NULL
Pizzanelli	NULL
,	NULL
M.	NULL
,	NULL
Tagliafico	NULL
,	NULL
E.	NULL
,	NULL
Balestri	NULL
,	NULL
R.	NULL
,	NULL
Trevisan	NULL
,	NULL
F.	NULL
,	NULL
Barbieri	NULL
,	NULL
D.	NULL
,	NULL
Franceschi	NULL
,	NULL
C.	NULL
,	NULL
Battini	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Ferrari	NULL
,	NULL
S.	NULL
Presence	NULL
of	NULL
a	NULL
functional	NULL
vitamin	NULL
D	NULL
receptor	NULL
does	NULL
not	NULL
correlate	NULL
with	NULL
vitamin	NULL
D	NULL
;	NULL
phenotypic	NULL
effects	NULL
in	NULL
myeloid	NULL
differentiation	NULL
.	NULL

Cell	NULL
Death	NULL
Differ	NULL
.	NULL

,	NULL
4	NULL
:	NULL
497-505	NULL
,	NULL
1997	NULL
.	NULL

Gudas	NULL
,	NULL
L.	NULL
J.	NULL
Retinoids	NULL
,	NULL
retinoid-responsive	NULL
genes	NULL
,	NULL
cell	NULL
differentiation	NULL
,	NULL
and	NULL
cancer	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

,	NULL
3	NULL
:	NULL
655-662	NULL
,	NULL
1992	NULL
.	NULL

Miller	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
Koceffler	NULL
,	NULL
H.	NULL
P.	NULL
In	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
differentiation	NULL
of	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
.	NULL

/n	NULL
:	NULL
A.	NULL
M.	NULL
Mauer	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Biology	NULL
of	NULL
Human	NULL
Leukemia	NULL
,	NULL
pp	NULL
.	NULL

152-176	NULL
.	NULL

Baltimore	NULL
and	NULL
London	NULL
:	NULL
The	NULL
John	NULL
Hopkins	NULL
University	NULL
Press	NULL
,	NULL
1990	NULL
.	NULL

Jin	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Kerner	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Hong	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
and	NULL
Pike	NULL
,	NULL
J.	NULL
W.	NULL
Transcriptional	NULL
activation	NULL
and	NULL
dimerization	NULL
functions	NULL
in	NULL
the	NULL
human	NULL
vitamin	NULL
D	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

,	NULL
10	NULL
:	NULL
945-957	NULL
,	NULL
1996	NULL
.	NULL

La	NULL
Vista	NULL
Picard	NULL
,	NULL
N.	NULL
,	NULL
Hobbs	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Pfahl	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Dawson	NULL
,	NULL
M.	NULL
I	NULL
.	NULL

The	NULL
receptor-DNA	NULL
complex	NULL
determines	NULL
the	NULL
retinoid	NULL
response	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
the	NULL
diversification	NULL
of	NULL
the	NULL
ligand	NULL
signal	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
;	NULL
4137-4146	NULL
,	NULL
1996	NULL
.	NULL

Asou	NULL
,	NULL
H.	NULL
,	NULL
Tashiro	NULL
,	NULL
S.	NULL
,	NULL
Hamamoto	NULL
,	NULL
K.	NULL
,	NULL
Otsuji	NULL
,	NULL
A.	NULL
,	NULL
Kita	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Kamada	NULL
,	NULL
N.	NULL
Establishment	NULL
of	NULL
a	NULL
human	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
Kasumi-1	NULL
)	NULL
with	NULL
8:21	NULL
chromosome	NULL
translocation	NULL
.	NULL

Blood	NULL
,	NULL
77	NULL
:	NULL
2031-2036	NULL
,	NULL
1991	NULL
.	NULL

Bennett	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Catovsky	NULL
,	NULL
D.	NULL
,	NULL
Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Flandrin	NULL
,	NULL
G.	NULL
,	NULL
Galton	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Gralnick	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
and	NULL
Sultan	NULL
,	NULL
C.	NULL
Proposals	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
the	NULL
acute	NULL
leukaemias	NULL
.	NULL

French-American-British	NULL
(	NULL
FAB	NULL
)	NULL
co-operative	NULL
group	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
33	NULL
:	NULL
451-458	NULL
,	NULL
1976	NULL
.	NULL

Yam	NULL
,	NULL
L.	NULL
T.	NULL
,	NULL
Li	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
and	NULL
Crosby	NULL
,	NULL
W.	NULL
H.	NULL
Cytochemical	NULL
identification	NULL
of	NULL
monocyte	NULL
and	NULL
granulocyte	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Pathol	NULL
.	NULL

,	NULL
55	NULL
:	NULL
283-290	NULL
,	NULL
1971	NULL
.	NULL

Drexler	NULL
,	NULL
H.	NULL
G.	NULL
Classification	NULL
of	NULL
acute	NULL
myeloid	NULL
leukemias	NULL
:	NULL
a	NULL
comparison	NULL
of	NULL
FAB	NULL
and	NULL
immunophenotyping	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
1	NULL
:	NULL
697-705	NULL
,	NULL
1987	NULL
.	NULL

Kozu	NULL
,	NULL
T.	NULL
,	NULL
Miyoshi	NULL
,	NULL
H.	NULL
,	NULL
Shimizu	NULL
,	NULL
K.	NULL
,	NULL
Maseki	NULL
,	NULL
N.	NULL
,	NULL
Kaneko	NULL
,	NULL
Y.	NULL
,	NULL
Asou	NULL
,	NULL
H.	NULL
,	NULL
Kamada	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Ohki	NULL
,	NULL
M.	NULL
Junctions	NULL
of	NULL
the	NULL
AML1/MTGS	NULL
(	NULL
ETO	NULL
)	NULL
fusion	NULL
are	NULL
constant	NULL
in	NULL
1	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
detected	NULL
by	NULL
reverse	NULL
transcription	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Blood	NULL
,	NULL
82	NULL
:	NULL
1270-1276	NULL
,	NULL
1993	NULL
.	NULL

Borrow	NULL
,	NULL
J.	NULL
,	NULL
Goddard	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Gibbons	NULL
,	NULL
B.	NULL
,	NULL
Katz	NULL
,	NULL
F.	NULL
,	NULL
Swirsky	NULL
,	NULL
D.	NULL
,	NULL
Fioretos	NULL
,	NULL
T.	NULL
,	NULL
Dube	NULL
,	NULL
L.	NULL
,	NULL
Winfield	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Kingston	NULL
,	NULL
J.	NULL
,	NULL
Hagemeijer	NULL
,	NULL
A.	NULL
,	NULL
Rees	NULL
,	NULL
J.	NULL
K.	NULL
H.	NULL
,	NULL
Lister	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Solomon	NULL
,	NULL
E.	NULL
Diagnosis	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
by	NULL
RT-PCR	NULL
:	NULL
detection	NULL
of	NULL
PML-RARA	NULL
and	NULL
RARA-PML	NULL
fusion	NULL
transcripts	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
82	NULL
:	NULL
529-540	NULL
,	NULL
1992	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
and	NULL
Gallagher	NULL
,	NULL
R.	NULL
E.	NULL
Continuous	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
human	NULL
myeloid	NULL
leukaemic	NULL
cells	NULL
in	NULL
suspension	NULL
culture	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
270	NULL
:	NULL
347-349	NULL
,	NULL
1977	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

The	NULL
HL-60	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
:	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
cellular	NULL
oncogene	NULL
expression	NULL
.	NULL

Blood	NULL
,	NULL
70	NULL
:	NULL
1233-1244	NULL
,	NULL
1987	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Donelli	NULL
,	NULL
A.	NULL
,	NULL
Manfredini	NULL
,	NULL
R.	NULL
,	NULL
Sarti	NULL
,	NULL
M.	NULL
,	NULL
Roncaglia	NULL
,	NULL
R.	NULL
,	NULL
Tagliafico	NULL
,	NULL
E.	NULL
,	NULL
Rossi	NULL
,	NULL
E.	NULL
,	NULL
Torelli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Torelli	NULL
,	NULL
U	NULL
.	NULL

Differential	NULL
effects	NULL
of	NULL
c-myb	NULL
and	NULL
c-fes	NULL
antisense	NULL
oligodeoxynucleotides	NULL
on	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
human	NULL
myeloid	NULL
leukemia	NULL
HL6O0	NULL
cells	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

,	NULL
7	NULL
:	NULL
543-548	NULL
,	NULL
1990	NULL
.	NULL

Brackman	NULL
,	NULL
D.	NULL
,	NULL
Lundjohansen	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Aarskog	NULL
,	NULL
D.	NULL
Expression	NULL
of	NULL
cell	NULL
surface	NULL
antigens	NULL
during	NULL
the	NULL
differentiation	NULL
of	NULL
HL60	NULL
cells	NULL
induced	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
,	NULL
retinoic	NULL
acid	NULL
and	NULL
DMSO	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
19	NULL
:	NULL
57-64	NULL
,	NULL
1995	NULL
.	NULL

Zhang	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Hetherington	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Gonzalez	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Chen	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
and	NULL
Tenen	NULL
,	NULL
D.	NULL
G.	NULL
Regulation	NULL
of	NULL
CD14	NULL
expression	NULL
during	NULL
monocytic	NULL
differentiation	NULL
induced	NULL
with	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
153	NULL
;	NULL
3276-3284	NULL
,	NULL
1994	NULL
.	NULL

Lubbert	NULL
,	NULL
M.	NULL
,	NULL
Herrmann	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
Expression	NULL
and	NULL
regulation	NULL
of	NULL
myeloid-specific	NULL
genes	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
myeloid	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
77	NULL
:	NULL
909-924	NULL
,	NULL
1991	NULL
.	NULL

Thomas	NULL
,	NULL
M.	NULL
L.	NULL
The	NULL
leukocyte	NULL
common	NULL
antigen	NULL
family	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
7	NULL
:	NULL
339-369	NULL
,	NULL
1989	NULL
.	NULL

MacDonald	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Swift	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
Przybyla	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
and	NULL
Chirgwin	NULL
,	NULL
J.	NULL
M.	NULL
Isolation	NULL
of	NULL
RNA	NULL
using	NULL
guanidinium	NULL
salts	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
152	NULL
:	NULL
219-227	NULL
,	NULL
1987	NULL
.	NULL

Grande	NULL
,	NULL
A.	NULL
,	NULL
Manfredini	NULL
,	NULL
R.	NULL
,	NULL
Tagliafico	NULL
,	NULL
E.	NULL
,	NULL
Balestri	NULL
,	NULL
R.	NULL
,	NULL
Pizzanelli	NULL
,	NULL
M.	NULL
,	NULL
Papa	NULL
,	NULL
S.	NULL
,	NULL
Zucchini	NULL
,	NULL
P.	NULL
,	NULL
Bonsi	NULL
,	NULL
L.	NULL
,	NULL
Bagnara	NULL
,	NULL
G.	NULL
,	NULL
Torelli	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
Ferrari	NULL
,	NULL
S.	NULL
All-frans	NULL
retinoic	NULL
acid	NULL
induces	NULL
simultaneously	NULL
granulocytic	NULL
differentiation	NULL
and	NULL
expression	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
in	NULL
HL	NULL
60	NULL
cells	NULL
.	NULL

Exp	NULL
.	NULL

Hematol	NULL
.	NULL

,	NULL
23	NULL
:	NULL
117-125	NULL
,	NULL
1995	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

MONOCYTIC	NULL
DIFFERENTIATION	NULL
OF	NULL
AML-M2	NULL
BLAST	NULL
CELLS	NULL
Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Ong	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Dyck	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
Nuclear	NULL
receptor	NULL
that	NULL
identifies	NULL
a	NULL
novel	NULL
retinoic	NULL
acid	NULL
response	NULL
pathway	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
345	NULL
:	NULL
224-229	NULL
,	NULL
1990.	NULL
.	NULL

Giguere	NULL
,	NULL
V.	NULL
,	NULL
Ong	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Segui	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
Identification	NULL
of	NULL
a	NULL
receptor	NULL
for	NULL
the	NULL
morphogen	NULL
retinoic	NULL
acid	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
330	NULL
:	NULL
624-629	NULL
,	NULL
1987	NULL
.	NULL

Baker	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
McDonnell	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Hughes	NULL
,	NULL
M.	NULL
,	NULL
Crisp	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Haussler	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Pike	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Shine	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
O'Malley	NULL
,	NULL
B.	NULL
W.	NULL
Cloning	NULL
and	NULL
expression	NULL
of	NULL
full-length	NULL
cDNA	NULL
encoding	NULL
human	NULL
vitamin	NULL
D	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
:	NULL
3294-3298	NULL
,	NULL
1988	NULL
.	NULL

Miyamoto	NULL
,	NULL
K.	NULL
,	NULL
Kesterson	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Yamamoto	NULL
,	NULL
H.	NULL
,	NULL
Taketani	NULL
,	NULL
Y.	NULL
,	NULL
Nishiwaki	NULL
,	NULL
E.	NULL
,	NULL
Tat-sumi	NULL
,	NULL
S.	NULL
,	NULL
Inoue	NULL
,	NULL
Y.	NULL
,	NULL
Morita	NULL
,	NULL
K.	NULL
,	NULL
Takeda	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Pike	NULL
,	NULL
J.	NULL
W.	NULL
Structural	NULL
organization	NULL
of	NULL
the	NULL
human	NULL
vitamin	NULL
D	NULL
receptor	NULL
chromosomal	NULL
gene	NULL
and	NULL
its	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

,	NULL
11	NULL
:	NULL
1165-1179	NULL
,	NULL
1997	NULL
.	NULL

Ferrero	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Goyert	NULL
,	NULL
S.	NULL
M.	NULL
Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
monocyte	NULL
differentiation	NULL
antigen	NULL
,	NULL
CD14	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
16	NULL
:	NULL
4173	NULL
,	NULL
1988	NULL
.	NULL

Zschunke	NULL
,	NULL
F.	NULL
,	NULL
Salmassi	NULL
,	NULL
A.	NULL
,	NULL
Kreipe	NULL
,	NULL
H.	NULL
,	NULL
Buck	NULL
,	NULL
F.	NULL
,	NULL
Parwaresch	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Radzun	NULL
,	NULL
H.	NULL
J.	NULL
cDNA	NULL
cloning	NULL
and	NULL
characterization	NULL
of	NULL
human	NULL
monocyte/macrophage	NULL
serine	NULL
esterase-1	NULL
.	NULL

Blood	NULL
,	NULL
78	NULL
:	NULL
506-512	NULL
,	NULL
1991	NULL
.	NULL

Kicfer	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Saphire	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Bauer	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Barr	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

The	NULL
cDNA	NULL
and	NULL
derived	NULL
amino	NULL
acid	NULL
sequences	NULL
of	NULL
human	NULL
and	NULL
bovine	NULL
bone	NULL
Gla	NULL
protein	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
18	NULL
:	NULL
1909	NULL
,	NULL
1990	NULL
.	NULL

Suggs	NULL
,	NULL
S.	NULL
V.	NULL
,	NULL
Wallace	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Hirose	NULL
,	NULL
T.	NULL
,	NULL
Kawashima	NULL
,	NULL
E.	NULL
H.	NULL
,	NULL
and	NULL
Itakura	NULL
,	NULL
K.	NULL
Use	NULL
of	NULL
synthetic	NULL
oligonucleotides	NULL
as	NULL
hybridization	NULL
probes	NULL
:	NULL
isolation	NULL
of	NULL
cloned	NULL
cDNA	NULL
sequences	NULL
for	NULL
human	NULL
B2-microglobulin	NULL
.	NULL

Biotechnology	NULL
,	NULL
24	NULL
:	NULL
140-144	NULL
,	NULL
1992	NULL
.	NULL

Liu	NULL
,	NULL
M.	NULL
,	NULL
Lee	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Cohen	NULL
,	NULL
M.	NULL
,	NULL
Bommakanti	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Freedman	NULL
,	NULL
L.	NULL
P.	NULL
Transcriptional	NULL
activation	NULL
of	NULL
the	NULL
Cdk	NULL
inhibitor	NULL
p21	NULL
by	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
leads	NULL
to	NULL
the	NULL
induced	NULL
differentiation	NULL
of	NULL
the	NULL
myelomonocytic	NULL
cell	NULL
line	NULL
U937	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
10	NULL
:	NULL
142-153	NULL
,	NULL
1996	NULL
.	NULL

Scott	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Mueller	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
S.	NULL
J.	NULL
E3	NULL
,	NULL
a	NULL
hematopoictic-specific	NULL
transcript	NULL
directly	NULL
regulated	NULL
by	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
.	NULL

Blood	NULL
,	NULL
88	NULL
:	NULL
2517-2530	NULL
,	NULL
1996	NULL
.	NULL

Matikainen	NULL
,	NULL
S.	NULL
,	NULL
Ronni	NULL
,	NULL
T.	NULL
,	NULL
Hurme	NULL
,	NULL
M.	NULL
,	NULL
Pine	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Julkunen	NULL
,	NULL
I.	NULL
Retinoic	NULL
acid	NULL
activates	NULL
interferon	NULL
regulatory	NULL
factor-1	NULL
gene	NULL
expression	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
88	NULL
:	NULL
114-123	NULL
,	NULL
1996	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Manfredini	NULL
,	NULL
R.	NULL
,	NULL
Tagliafico	NULL
,	NULL
E.	NULL
,	NULL
Rossi	NULL
,	NULL
E.	NULL
,	NULL
Donelli	NULL
,	NULL
A.	NULL
,	NULL
Torelli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Torelli	NULL
,	NULL
U.	NULL
Noncoordinated	NULL
expression	NULL
of	NULL
$	NULL
6	NULL
,	NULL
S11	NULL
,	NULL
and	NULL
$	NULL
14	NULL
ribosomal	NULL
protein	NULL
genes	NULL
in	NULL
leukemic	NULL
blast	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
50	NULL
:	NULL
5825-5828	NULL
,	NULL
1990	NULL
.	NULL

Hennighausen	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Lubon	NULL
,	NULL
H.	NULL
Interaction	NULL
of	NULL
protein	NULL
with	NULL
DNA	NULL
in	NULL
vitro	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
152	NULL
;	NULL
721-735	NULL
,	NULL
1987	NULL
.	NULL

Burnette	NULL
,	NULL
W.	NULL
N.	NULL
Western	NULL
blotting	NULL
:	NULL
electrophoretic	NULL
transfer	NULL
of	NULL
proteins	NULL
from	NULL
SDS-polyacrylamide	NULL
gels	NULL
to	NULL
unmodified	NULL
nitrocellulose	NULL
and	NULL
radiographic	NULL
detection	NULL
with	NULL
antibody	NULL
and	NULL
radioiodinated	NULL
protein	NULL
A.	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
172	NULL
:	NULL
195-203	NULL
,	NULL
1981	NULL
.	NULL

Manfredini	NULL
,	NULL
R.	NULL
,	NULL
Grande	NULL
,	NULL
A.	NULL
,	NULL
Tagliafico	NULL
,	NULL
E.	NULL
,	NULL
Barbieri	NULL
,	NULL
D.	NULL
,	NULL
Zucchini	NULL
,	NULL
P.	NULL
,	NULL
Citro	NULL
,	NULL
G.	NULL
,	NULL
Zupi	NULL
,	NULL
G.	NULL
,	NULL
Franceschi	NULL
,	NULL
C.	NULL
,	NULL
Torelli	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
Ferrari	NULL
,	NULL
S.	NULL
Inhibition	NULL
of	NULL
c-fes	NULL
expression	NULL
by	NULL
an	NULL
antisense	NULL
oligomer	NULL
causes	NULL
apoptosis	NULL
of	NULL
HL6O	NULL
cells	NULL
induced	NULL
to	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
178	NULL
:	NULL
381-389	NULL
,	NULL
1993	NULL
.	NULL

Umesono	NULL
,	NULL
K.	NULL
,	NULL
Murakami	NULL
,	NULL
K.	NULL
K.	NULL
,	NULL
Thompson	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
Direct	NULL
repeats	NULL
as	NULL
selective	NULL
response	NULL
elements	NULL
for	NULL
the	NULL
thyroid	NULL
hormone	NULL
,	NULL
retinoic	NULL
acid	NULL
,	NULL
and	NULL
vitamin	NULL
D	NULL
;	NULL
receptors	NULL
.	NULL

Cell	NULL
,	NULL
65	NULL
:	NULL
1255-1266	NULL
,	NULL
1991	NULL
.	NULL

Kadonaga	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
Affinity	NULL
purification	NULL
of	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
:	NULL
5889-5893	NULL
,	NULL
1986	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Battini	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Molinari	NULL
,	NULL
S.	NULL
Specific	NULL
binding	NULL
to	NULL
vitamin	NULL
D	NULL
response	NULL
elements	NULL
of	NULL
chicken	NULL
intestinal	NULL
DNA-binding	NULL
activity	NULL
is	NULL
not	NULL
related	NULL
to	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

,	NULL
8	NULL
:	NULL
173-181	NULL
,	NULL
1994	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

3811	NULL
Ozono	NULL
,	NULL
K.	NULL
,	NULL
Liao	NULL
,	NULL
J.	NULL
,	NULL
Kerner	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Scott	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
Pike	NULL
,	NULL
J.	NULL
W.	NULL
The	NULL
vitamin	NULL
D-responsive	NULL
element	NULL
in	NULL
the	NULL
human	NULL
osteocalcin	NULL
gene	NULL
.	NULL

Association	NULL
with	NULL
a	NULL
nuclear	NULL
proto-oncogene	NULL
enhancer	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
265	NULL
:	NULL
21881-21888	NULL
,	NULL
1990	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
Battini	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Pike	NULL
,	NULL
W.	NULL
J.	NULL
Functional	NULL
analysis	NULL
of	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
chicken	NULL
calbindin	NULL
D	NULL
;	NULL
,	NULL
Â¢	NULL
.	NULL

Adv	NULL
.	NULL

Exp	NULL
.	NULL

Med	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
269	NULL
:	NULL
21-25	NULL
,	NULL
1990	NULL
.	NULL

Herbomel	NULL
,	NULL
P.	NULL
,	NULL
Bourachot	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Yaniv	NULL
,	NULL
M.	NULL
Two	NULL
distinct	NULL
enhancers	NULL
with	NULL
different	NULL
cell	NULL
specificities	NULL
coexist	NULL
in	NULL
the	NULL
regulatory	NULL
region	NULL
of	NULL
polyoma	NULL
.	NULL

Cell	NULL
,	NULL
39	NULL
:	NULL
653-662	NULL
,	NULL
1984.	NULL
.	NULL

Lefebvre	NULL
,	NULL
P.	NULL
,	NULL
Gaub	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Tahayato	NULL
,	NULL
A.	NULL
,	NULL
Rochette	NULL
Egly	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Formstecher	NULL
,	NULL
P.	NULL
Protein	NULL
phosphatases	NULL
1	NULL
and	NULL
2A	NULL
regulate	NULL
the	NULL
transcriptional	NULL
and	NULL
DNA	NULL
binding	NULL
activities	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
270	NULL
:	NULL
10806-10816	NULL
,	NULL
1995	NULL
.	NULL

Ross	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Darwish	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Moss	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
Vitamin	NULL
D-influenced	NULL
gene	NULL
expression	NULL
via	NULL
a	NULL
ligand-independent	NULL
,	NULL
receptor-DNA	NULL
complex	NULL
intermediate	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
:	NULL
9257-9260	NULL
,	NULL
1993	NULL
.	NULL

Matkovits	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Christakos	NULL
,	NULL
S.	NULL
Ligand	NULL
occupancy	NULL
is	NULL
not	NULL
required	NULL
for	NULL
vitamin	NULL
D	NULL
receptor	NULL
and	NULL
retinoid	NULL
receptor-mediated	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

,	NULL
9	NULL
:	NULL
232-242	NULL
,	NULL
1995	NULL
.	NULL

Darwish	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Burmester	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Moss	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
Phosphorylation	NULL
is	NULL
involved	NULL
in	NULL
transcriptional	NULL
activation	NULL
by	NULL
the	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
receptor	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1167	NULL
:	NULL
29-36	NULL
,	NULL
1993	NULL
.	NULL

Liu	NULL
,	NULL
M.	NULL
,	NULL
Iavarone	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Freedman	NULL
,	NULL
L.	NULL
P.	NULL
Transcriptional	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
p21	NULL
(	NULL
WAFL/CIP1	NULL
)	NULL
gene	NULL
by	NULL
retinoic	NULL
acid	NULL
receptor	NULL
.	NULL

Correlation	NULL
with	NULL
retinoid	NULL
induction	NULL
of	NULL
U937	NULL
cell	NULL
differentiation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
277	NULL
:	NULL
31723-31728	NULL
,	NULL
1996	NULL
.	NULL

Schwaller	NULL
,	NULL
J.	NULL
,	NULL
Pabst	NULL
,	NULL
T.	NULL
,	NULL
Koceffler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Niklaus	NULL
,	NULL
G.	NULL
,	NULL
Loctscher	NULL
,	NULL
P.	NULL
,	NULL
Fey	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
and	NULL
Tobler	NULL
,	NULL
A	NULL
.	NULL

Expression	NULL
and	NULL
regulation	NULL
of	NULL
G	NULL
,	NULL
cell-cycle	NULL
inhibitors	NULL
(	NULL
pl6INK4A	NULL
,	NULL
pl5INK4B	NULL
,	NULL
p18INKA4C	NULL
,	NULL
p19INK4D	NULL
)	NULL
in	NULL
human	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
and	NULL
normal	NULL
myeloid	NULL
cells	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
17	NULL
:	NULL
54-63	NULL
,	NULL
1997	NULL
.	NULL

Irvine	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Berney	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
Francis	NULL
,	NULL
G.	NULL
E.	NULL
Dissociation	NULL
of	NULL
the	NULL
proliferation	NULL
and	NULL
differentiation	NULL
stimuli	NULL
of	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
4	NULL
:	NULL
203-209	NULL
,	NULL
1990	NULL
.	NULL

Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Fenaux	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Degos	NULL
,	NULL
L.	NULL
Retinoid	NULL
differentiation	NULL
therapy	NULL
in	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

FASEB	NULL
J.	NULL
,	NULL
10	NULL
:	NULL
1025-1030	NULL
,	NULL
1996	NULL
.	NULL

Asou	NULL
,	NULL
H.	NULL
,	NULL
Koike	NULL
,	NULL
M.	NULL
,	NULL
Elstner	NULL
,	NULL
E.	NULL
,	NULL
Cambell	NULL
,	NULL
M.	NULL
,	NULL
Le	NULL
,	NULL
J.	NULL
,	NULL
Uskokovic	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Kamada	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
19-Nor	NULL
vitamin-D	NULL
analogs	NULL
:	NULL
a	NULL
new	NULL
class	NULL
of	NULL
potent	NULL
inhibitors	NULL
of	NULL
proliferation	NULL
and	NULL
inducers	NULL
of	NULL
differentiation	NULL
of	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
lines	NULL
.	NULL

Blood	NULL
,	NULL
92	NULL
:	NULL
2441-2449	NULL
,	NULL
1998	NULL
.	NULL

Botling	NULL
,	NULL
J.	NULL
,	NULL
Oberg	NULL
,	NULL
F.	NULL
,	NULL
Torma	NULL
,	NULL
H.	NULL
,	NULL
Tuohimaa	NULL
,	NULL
P.	NULL
,	NULL
Blauer	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Nilsson	NULL
,	NULL
K.	NULL
Vitamin	NULL
D	NULL
;	NULL
-	NULL
and	NULL
retinoic	NULL
acid-induced	NULL
monocytic	NULL
differentiation	NULL
:	NULL
interactions	NULL
between	NULL
the	NULL
endogenous	NULL
vitamin	NULL
D	NULL
;	NULL
receptor	NULL
,	NULL
retinoic	NULL
acid	NULL
receptors	NULL
,	NULL
and	NULL
retinoid	NULL
X	NULL
receptors	NULL
in	NULL
U-937	NULL
cells	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

,	NULL
7	NULL
:	NULL
1239-1249	NULL
,	NULL
1996	NULL
.	NULL

Nakajima	NULL
,	NULL
H.	NULL
,	NULL
Kizaki	NULL
,	NULL
M.	NULL
,	NULL
Ueno	NULL
,	NULL
H.	NULL
,	NULL
Muto	NULL
,	NULL
A.	NULL
,	NULL
Takayama	NULL
,	NULL
N.	NULL
,	NULL
Matsushita	NULL
,	NULL
H.	NULL
,	NULL
Sonoda	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Ikeda	NULL
,	NULL
Y.	NULL
All-frans	NULL
and	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
enhance	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
-induced	NULL
monocytic	NULL
differentiation	NULL
of	NULL
U937	NULL
cells	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
20	NULL
:	NULL
665-676	NULL
,	NULL
1996	NULL
.	NULL

Cao	NULL
,	NULL
X.	NULL
,	NULL
Teitelbaum	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Zhu	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Zhang	NULL
,	NULL
L.	NULL
,	NULL
Feng	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
Ross	NULL
,	NULL
F.	NULL
P.	NULL
Competition	NULL
for	NULL
a	NULL
unique	NULL
response	NULL
element	NULL
mediates	NULL
retinoic	NULL
acid	NULL
inhibition	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
-stimulated	NULL
transcription	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
277	NULL
:	NULL
20650-20654	NULL
,	NULL
1996	NULL
.	NULL

Wiese	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Ubland	NULL
Smith	NULL
,	NULL
A.	NULL
,	NULL
Ross	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Prahl	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
Up-regulation	NULL
of	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
in	NULL
response	NULL
to	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
results	NULL
from	NULL
ligand-induced	NULL
stabilization	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
267	NULL
:	NULL
20082-20086	NULL
,	NULL
1992	NULL
.	NULL

Geyer	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
Meyuhas	NULL
,	NULL
O.	NULL
,	NULL
Perry	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
and	NULL
Johnson	NULL
,	NULL
L.	NULL
F.	NULL
Regulation	NULL
of	NULL
ribosomal	NULL
protein	NULL
mRNA	NULL
content	NULL
and	NULL
translation	NULL
in	NULL
growth-stimulated	NULL
mouse	NULL
fibroblasts	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
2	NULL
:	NULL
685-693	NULL
,	NULL
1982	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AACâR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Induction	NULL
of	NULL
a	NULL
Functional	NULL
Vitamin	NULL
D	NULL
Receptor	NULL
in	NULL
all-trans	NULL
-Retinoic	NULL
Acid-induced	NULL
Monocytic	NULL
Differentiation	NULL
of	NULL
M2-type	NULL
Leukemic	NULL
Blast	NULL
Cells	NULL
Rossella	NULL
Mantfredini	NULL
,	NULL
Francesca	NULL
Trevisan	NULL
,	NULL
Alexis	NULL
Grande	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1999	NULL
;	NULL
59:3803-3811	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/59/15/3803	NULL
Cited	NULL
articles	NULL
Citing	NULL
articles	NULL
This	NULL
article	NULL
cites	NULL
74	NULL
articles	NULL
,	NULL
31	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/59/1	NULL
5/3803	NULL
full	NULL
#	NULL
reft-list-1	NULL
This	NULL
article	NULL
has	NULL
been	NULL
cited	NULL
by	NULL
3	NULL
HighWire-hosted	NULL
articles	NULL
.	NULL

Access	NULL
the	NULL
articles	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/59/1	NULL
5/3803	NULL
.full	NULL
#	NULL
related-urls	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/59/15/3803	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

